

BMJ Open

Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): a protocol for prospective, observational, single centre study



Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013218
Article Type:	Protocol
Date Submitted by the Author:	27-Jun-2016
Complete List of Authors:	Adamski, Piotr; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Principles of Clinical Medicine Ostrowska, Małgorzata; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Principles of Clinical Medicine Sikora, Joanna; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Pharmacology and Therapy Obońska, Karolina; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Cardiology and Internal Medicine Buszko, Katarzyna; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Theoretical Foundations of Biomedical Science and Medical Informatics Krintus, Magdalena; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Laboratory Medicine Sypniewska, Grazyna; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Laboratory Medicine Marszał, Michał; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Medicinal Chemistry Kozinski, Marek; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Principles of Clinical Medicine Kubica, Jacek; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Cardiology and Internal Medicine
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Pharmacology and therapeutics
Keywords:	NSTEMI, pharmacodynamics, pharmacokinetics, STEMI, ticagrelor

SCHOLARONE™
Manuscripts

Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): a protocol for prospective, observational, single centre study

Piotr Adamski,^{1†} Małgorzata Ostrowska,¹ Joanna Sikora,² Karolina Obońska,³ Katarzyna Buszko,⁴ Magdalena Krintus,⁵ Grażyna Sypniewska,⁵ Michał Piotr Marszałł,⁶ Marek Koziński,¹ Jacek Kubica³

¹Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

²Department of Pharmacology and Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

³Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁴Department of Theoretical Foundations of Biomedical Science and Medical Informatics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁵Department of Laboratory Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁶Department of Medicinal Chemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

† Corresponding author

Address for correspondence: Piotr Adamski, Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, 9 Skłodowskiej-Curie Street, 85-094 Bydgoszcz, Poland; Tel.: +48 52 5854023, Fax: +48 52 5854024; E-mail: piotr.adamski@wp.eu

Keywords: NSTEMI, pharmacodynamics, pharmacokinetics, STEMI, ticagrelor

Word count: 2135

ABSTRACT

Introduction

Ischaemic heart disease is the most common cause of death in the world and acute myocardial infarction (AMI) remains its common lethal presentation. The most often applied classification of AMI is based on electrocardiographic findings and distinguishes ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). Epidemiology, clinical approach and early outcomes differ between patients with these two types of AMI. Ticagrelor is a P2Y₁₂ receptor inhibitor which is the first line treatment in both STEMI and NSTEMI patients. Available data suggest that STEMI diagnosis can be associated with lower plasma concentrations of ticagrelor in the first hours of AMI, but currently there are no studies directly comparing ticagrelor's pharmacokinetics or antiplatelet effect in STEMI and NSTEMI patients.

Methods and analysis

The PINPOINT study is a phase IV, single centre, investigator-initiated, prospective, observational study designed to compare pharmacokinetics and pharmacodynamics of ticagrelor in STEMI and NSTEMI patients designated to invasive strategy. Based on the internal pilot study, the trial is expected to include at least 23 patients with each AMI type. All subjects will receive 180 mg loading dose of ticagrelor. The primary end-point of the study is area under the plasma concentration-time curve ($AUC_{(0-6)}$) for ticagrelor for the first 6 hours after the loading dose of ticagrelor. Secondary end-points include various pharmacokinetic features of ticagrelor and its active metabolite (AR-C124910XX), and evaluation of platelet reactivity by VASP assay and multiple electrode aggregometry within 12 hours from ticagrelor loading dose.

Ethics and dissemination

The study received approval from the Local Ethics Committee to conduct the study (Komisja Bioetyczna Uniwersytetu Mikołaja Kopernika w Toruniu przy Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy; approval reference number KB 617/2015). The study results will be disseminated through conference presentations and publication in peer-reviewed journal.

Trial Registration: ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015)

INTRODUCTION

According to the World Health Organization ischaemic heart disease is the most common cause of death in the world. In year 2012 alone it was responsible for 7.4 million deaths worldwide.[1] Current data show that ischaemic heart disease itself can be accounted for even up to 20% of all deaths in the developed or developing countries.[2]

Although the efficacy of acute myocardial infarction (AMI) treatment has substantially improved in the last decades, AMI still remains dangerous and lethal presentation of ischaemic heart disease. Third Universal Definition of Myocardial Infarction recognizes five different types of myocardial infarction based on their pathomechanism or clinical cause.[3] However, a different classification is routinely applied in everyday practice to facilitate the immediate choice of treatment strategy in AMI patients. This classification is based on the electrocardiographic findings and distinguishes ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI).[3]

Over the past years the incidence of STEMI has decreased, while the occurrence of NSTEMI has slightly increased, and currently STEMI and NSTEMI occur almost equally often.[4, 5] Short-term mortality is higher in STEMI patients, however the mortality rates become comparable or even higher in NSTEMI patients at long-term follow-up.[6-9]

In STEMI, which is usually caused by acute total occlusion of coronary artery, immediate primary percutaneous coronary intervention (PCI) is the mainstay of treatment.[10] In NSTEMI the therapeutic strategy and its timing depends on the risk stratification. The urgency of recommended invasive coronary evaluation in this type of AMI varies from <2 hours in very high risk patients (immediate invasive strategy), through <24 hours in high risk patients (early invasive strategy), to <72 hours in intermediate risk patients (invasive strategy).[9]

1
2
3 Complementary to coronary revascularization, dual antiplatelet therapy consisting of
4 aspirin on top of a P2Y12 receptor inhibitor remains the cornerstone of pharmacological
5 treatment in AMI patients, including both STEMI and NSTEMI. The European Society of
6 Cardiology (ESC) guidelines recommend use of ticagrelor or prasugrel as the first line P2Y12
7 receptor inhibitor in patients with STEMI and NSTEMI (class of recommendation I, level of
8 evidence B).[9, 10] Unlike prasugrel, ticagrelor can be used also in conservatively treated
9 patients and in those who are likely to undergo coronary artery bypass grafting.
10
11
12
13
14
15
16
17

18 The importance of platelet P2Y12 receptor blockade in patients with AMI derives
19 from the essential role exerted by platelet activation and aggregation in the pathophysiology
20 of acute coronary syndromes (ACS).[11] Inadequate platelet inhibition during treatment with
21 P2Y12 receptor inhibitors, defined as high platelet reactivity (HPR), is an important risk
22 factor for stent thrombosis and can be associated with increased mortality.[12] Therefore,
23 effective and rapid suppression of platelet activation is pivotal in patients with AMI treated
24 with PCI. Noteworthy, it has been reported that platelet inhibition by ticagrelor and its active
25 metabolite (AR-C124910XX) is proportional to their plasma concentrations.[13]
26
27
28
29
30
31
32
33
34
35

36 Impact of numerous clinical features on plasma concentration and pharmacodynamics
37 of ticagrelor has been inspected. Genetic effects, gender, age, concomitant food intake or
38 preloading with clopidogrel have at most minimal influence on pharmacokinetics of
39 ticagrelor, which does not translate into any clinically significant differences in the degree of
40 platelet inhibition.[14-17] On the other hand, morphine administration has been shown to
41 affect pharmacokinetic profile as well as antiplatelet effect of ticagrelor not only in healthy
42 volunteers, but also in AMI patients.[18-20] Negative impact of morphine on the intestinal
43 absorption has been proposed as an explanation for the observed interactions, while no
44 evidence was found that morphine affects ticagrelor conversion to its active metabolite.[19,
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 study (Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in
4 Patients with Acute Myocardial Infarction) suggests that clinical presentation as STEMI when
5 compared with NSTEMI is independently associated with lower plasma concentrations of
6 ticagrelor.[19]
7
8
9

10
11 Even though ticagrelor shows more potent and prompt platelet inhibition than
12 clopidogrel, it still fails to provide desired antiplatelet effect in the first hours after the loading
13 dose (LD) in all STEMI patients.[22] The data on proportion of NSTEMI patients loaded with
14 ticagrelor who are at risk of HPR during peri-PCI period is sparse, however as expected
15 ticagrelor has been shown to provide stronger platelet blockade than clopidogrel in this
16 clinical setting.[23] Solely a pharmacodynamic study by Laine et al. reported that platelet
17 reactivity assessed with the platelet vasodilator-stimulated phosphoprotein (VASP) assay after
18 administration of a 180 mg ticagrelor LD was not uniform among ACS patients, but when
19 grouped by ACS type (STEMI, NSTEMI and unstable angina) it appeared to be similar
20 (p=0.9). However, the authors assessed the antiplatelet effect of ticagrelor only once in each
21 patient and the time of blood sampling differed substantially among trial participants.
22 Additionally, blood samples for pharmacodynamic evaluation were obtained between 6 and
23 24 hours after ticagrelor LD, so the first crucial hours after PCI were not covered by the
24 analysis.[24]
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 The PLATO (Platelet Inhibition and Patient Outcomes) trial has shown superior
44 efficacy of ticagrelor to clopidogrel in ACS patients. This superiority was demonstrated in
45 most of the analysed subgroups, including patients with STEMI and NSTEMI.[25]
46 Nevertheless, epidemiology, clinical approach and early outcomes differ between patients
47 with these two types of AMI, while recommended dosing regimens of ticagrelor are identical
48 in both clinical settings.[9, 10] Currently, there are no data on direct comparison of
49 ticagrelor's pharmacokinetics in the mentioned types of AMI, while STEMI patients may be at
50
51
52
53
54
55
56
57
58
59
60

1
2
3 risk of having lower plasma concentrations of ticagrelor in the most crucial time during early
4 hours of AMI treatment.[19] Similarly, potential differences in ticagrelor's antiplatelet effects
5
6
7 between STEMI and NSTEMI have not been defined yet. Therefore, we decided to verify
8
9 whether pharmacokinetics and pharmacodynamics of ticagrelor differ between STEMI and
10
11 NSTEMI patients, which we believe could provide a valuable insight into our knowledge
12
13 regarding modern treatment of AMI patients.
14

15 16 17 **METHODS AND ANALYSIS**

18 19 20 **Study objectives**

21
22
23 The PINPOINT study is designed to compare pharmacokinetics and
24
25 pharmacodynamics of ticagrelor and its active metabolite (AR-C124910XX) in patients with
26
27 STEMI and NSTEMI designated to invasive strategy.
28

29 30 31 **Study design**

32
33
34 The PINPOINT study is a phase IV, single centre, investigator-initiated, prospective,
35
36 observational, pharmacokinetic-pharmacodynamic study. After admission to the study centre
37
38 (Cardiology Clinic, Dr. A. Jurasz University Hospital, Bydgoszcz, Poland) and confirmation
39
40 of STEMI or NSTEMI diagnosis, patients will be screened for eligibility for the study. Each
41
42 patient will provide a written informed consent to participate in the trial. All included patients
43
44 will receive orally a 300 mg LD of plain aspirin and a 180 mg LD of ticagrelor in integral
45
46 tablets with 250 mL of tap water. Subsequently, all patients will undergo a coronary
47
48 angiography followed by PCI, if required. Blood samples for pharmacokinetic and
49
50 pharmacodynamic assessment will be drawn at eight predefined time points according to the
51
52 blood sampling schedule already used at our site in a previous study (pre-treatment baseline,
53
54 30 min, 1h, 2h, 3h, 4h, 6h and 12h post ticagrelor LD - as shown in Figure 1).[26]
55
56
57
58
59
60

Study population

The study population will include consecutive adult, male or non-pregnant female STEMI and NSTEMI patients, designated to invasive strategy. Full list of inclusion and exclusion criteria are presented in Table 1.

Table 1. Inclusion and exclusion criteria of the PINPOINT study.

Inclusion criteria	Exclusion criteria
provision of informed consent prior to any study specific procedures	treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrolment
diagnosis of STEMI or NSTEMI	hypersensitivity to ticagrelor
male or non-pregnant female, 18 years old and older	current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin
provision of informed consent for angiography and PCI	active bleeding
	history of intracranial haemorrhage
	recent gastrointestinal bleeding (within 30 days)
	history of coagulation disorders
	history of moderate or severe hepatic impairment
	history of major surgery or severe trauma (within 3 months)
	second or third degree atrioventricular block during screening for eligibility
	patient required dialysis
	manifest infection or inflammatory state
	Killip class III or IV during screening for eligibility
	respiratory failure
	current therapy with strong CYP3A inhibitors or strong CYP3A inducers

NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention;
STEMI: ST-elevation myocardial infarction.

Assessment of pharmacokinetics

Blood plasma concentrations of ticagrelor and AR-C124910XX in samples obtained at all eight predefined time points (Figure 1) will be evaluated using liquid chromatography

1
2
3 mass spectrometry coupled with tandem mass spectrometry.
4
5

6 **Assessment of pharmacodynamics**

7
8

9 Platelet VASP assay will be applied to all study participants at all predefined time
10 points. Multiple electrode aggregometry (MEA) will be used at all predefined time points
11 (Figure 1) for all study participants with the exception of those treated with glycoprotein
12 IIb/IIIa (GP IIb/IIIa) receptor inhibitors as this therapy may affect the results of platelet
13 reactivity assessment with MEA (Figure 2).
14
15
16
17
18
19

20 **Treatment**

21

22 All patients included in the trial will be treated according to the current ESC guidelines.
23 Standard therapy will include aspirin, ticagrelor, beta-blockers, statins, and angiotensin-
24 converting enzyme inhibitors or angiotensin II receptor blockers, if not contraindicated. The
25 type of implanted stent and the choice of the access site for the coronary invasive procedure
26 (radial or femoral) will be at the discretion of the operator. Administration of GP IIb/IIIa
27 receptor inhibitors will be restricted only to bailout situations. Interventional cardiologists will
28 be encouraged to use manual thrombectomy in case of visible thrombus.
29
30
31
32
33
34
35
36
37
38
39

40 **Study endpoints**

41

42 The primary end-point of the study is area under the plasma concentration-time curve
43 ($AUC_{(0-6)}$) for ticagrelor for the first 6 hours after LD of ticagrelor. Secondary end-points
44 include $AUC_{(0-6)}$ for AR-C124910XX, area under the plasma concentration-time curve
45 ($AUC_{(0-12)}$) for ticagrelor for the first 12 hours after LD of ticagrelor, $AUC_{(0-12)}$ for AR-
46 C124910XX, maximum concentration (C_{max}) of ticagrelor and AR-C124910XX, time to
47 maximum concentration (t_{max}) for ticagrelor and AR-C124910XX, platelet reactivity index
48 (PRI) assessed by the VASP assay, platelet reactivity assessed by MEA, percentage of
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 patients with HPR after LD of ticagrelor assessed with the VASP assay and MEA, time to
4 reach platelet reactivity below the cut-off value for HPR evaluated with the VASP assay and
5 MEA.
6
7
8
9

10 **Statistical analysis**

11
12 The continuous variables in the both study groups will be compared by t-test for
13 normally distributed values as assessed by Kolmogorov-Smirnov test. Otherwise, the Mann-
14 Whitney U test will be used. Proportions will be compared by the chi-square test when
15 appropriate. Pharmacokinetic calculations and plots will be made using dedicated software.
16
17
18
19
20
21
22

23 **Determination of sample size**

24
25 Since there is no reference study comparing pharmacokinetics of ticagrelor in STEMI
26 and NSTEMI patients, we decided to perform an internal pilot study of at least 15 patients
27 with each type of AMI for estimating the final sample size. Eventually, the pilot study
28 population comprised of 45 patients (15 with NSTEMI and 30 with STEMI). This included all
29 consecutively enrolled study participants who entered the trial until the minimum planned
30 number of patients was reached in the less numerous group (NSTEMI).
31
32
33
34
35
36
37
38

39 The means and standard deviations of $AUC_{(0-6)}$ for ticagrelor in the first 30 STEMI
40 patients and 15 NSTEMI patients were 2382 ± 2282 and 6406 ± 4082 ng*h/ml, respectively.
41 Based on these results and assuming a two-sided alpha value of 0.05, we calculated, using the
42 t-test for independent variables, that enrolment of at least 23 patients in each study arm would
43 provide a 95% power to demonstrate a significant difference in $AUC_{(0-6)}$ for ticagrelor
44 between patients with different type of MI.
45
46
47
48
49
50
51
52

53 **ETHICS AND DISSEMINATION**

54 **Ethics**

55
56
57
58
59
60

The study will be conducted in accordance with the principles contained in the Declaration of Helsinki and Good Clinical Practice guidelines. The study received a favourable ethical opinion and approval from the Local Ethics Committee to conduct the study (Komisja Bioetyczna Uniwersytetu Mikołaja Kopernika w Toruniu przy Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy; study approval reference number KB 617/2015). Each patient will provide a written informed consent to participate in the study.

Safety

The following safety endpoints will be recorded: all-cause death, recurrent myocardial infarction according to the Third Universal Definition of Myocardial Infarction, stroke, and transient ischemic attack according to definitions used in the PLATO trial, definite stent thrombosis according to the Academic Research Consortium criteria, minor and major bleedings according to the TIMI (thrombolysis in myocardial infarction) criteria, dyspnea adverse events according to criteria used in the PLATO trial, bradyarrhythmic events according to criteria used in the PLATO trial.

Present status

The approval of the Local Ethic Committee was obtained on September 29, 2015. On November 9, 2015 the PINPOINT study was registered on ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT02602444). The first patient was enrolled in November 2015. The baseline characteristics of patients included in the pilot study are presented in Table 2.

Table 2. Baseline characteristics of patients included in the internal pilot study.

	STEMI (n=30)	NSTEMI (n=15)
Age [years]	62.3 ± 8.8	63.9 ± 9.7
Age ≥ 70 years	6 (20.0%)	4 (26.7%)
Female	6 (20.0%)	5 (33.3%)

BMI [kg/m ²]	28.6 ± 4.1	27.8 ± 4.2
Hypertension	10 (33.3%)	10 (66.7%)
Diabetes mellitus	6 (20.0%)	2 (13.3%)
Dyslipidaemia	27 (90.0%)	14 (93.3%)
Current smoker	13 (43.3%)	5 (33.3%)
Prior MI	0	2 (13.3%)
Prior PCI	2 (6.7%)	3 (20.0%)
Prior CABG	0	0
Congestive heart failure	0	0
Nonhemorrhagic stroke	0	0
Peripheral arterial disease	1 (3.3%)	2 (13.3%)
Chronic renal disease	0	0
Chronic obstructive pulmonary disease	0	0
Gout	1 (3.3%)	1 (6.7%)

BMI: body mass index; CABG: coronary artery bypass surgery; MI: myocardial infarction; NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction. Data are shown as mean ± standard deviation or number (%).

Dissemination of results

Results of the PINPOINT study will be disseminated through conference presentations and peer-reviewed journals. The results will also be made available through study record website at ClinicalTrials.gov.

SUMMARY

Is it unknown whether ticagrelor's pharmacokinetic profile and antiplatelet effect are uniform in STEMI and NSTEMI patients, who are a very heterogeneous population. The PINPOINT trial is expected to be the first study to elucidate whether diagnosis of STEMI is associated with poorer absorption and subsequently weaker antiplatelet action of ticagrelor when compared with NSTEMI patients.

Contributors

JK and PA conceived the study. JK and PA wrote the study protocol with consultation from

1
2
3 MO, JS, KO, KB, MKr, GS, MM and MKo. Subsequently JK, PA, MO, JS, KO, KB, MKr,
4
5 GS, MM and MKo revised the manuscript critically for important intellectual content. All the
6
7 authors read and approved the final manuscript.
8
9

10 11 **Competing interests**

12
13
14 Dr. Jacek Kubica received a consulting fee from AstraZeneca. Dr. Marek Koziński
15
16 received honoraria for lectures from AstraZeneca. All other authors have reported that they
17
18 have no relationships relevant to the contents of this paper to disclose.
19

20 21 **Funding**

22
23
24 The study is funded by Collegium Medicum of Nicolaus Copernicus University and
25
26 did not receive any external funding.
27
28

29 30 **Ethics approval**

31
32
33 Local Ethics Committee: Komisja Bioetyczna Uniwersytetu Mikołaja Kopernika w
34
35 Toruniu przy Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy (study approval
36
37 reference number: KB 617/2015).
38
39

40 41 **References**

- 42
43
44 1. <http://www.who.int/mediacentre/factsheets/fs310/en/> (Date accessed: June 2016)
45
46 2. Townsend N, Nichols M, Scarborough P, et al. Cardiovascular disease in Europe-
47
48 epidemiological update 2015. *Eur Heart J* 2015;36:2696-705.
49
50 3. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial
51
52 infarction. *Eur Heart J* 2012;33:2551-67.
53
54 4. McManus DD, Gore J, Yarzebski J, et al. Recent trends in the incidence, treatment, and
55
56 outcomes of patients with STEMI and NSTEMI. *Am J Med* 2011;124:40-7.
57
58
59
60

- 1
2
3 5. Gierlotka M, Zdrojewski T, Wojtyniak B, et al. Incidence, treatment, in-hospital mortality
4 and one-year outcomes of acute myocardial infarction in Poland in 2009-2012-
5 nationwide AMI-PL database. *Kardiol Pol* 2015;73:142-58.
6
7
- 8
9 6. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission
10 electrocardiogram in acute coronary syndromes. *JAMA* 1999;281:707-13.
11
12
- 13 7. Mandelzweig L, Battler A, Boyko V, et al. The Second Euro Heart Survey on Acute
14 Coronary Syndromes: characteristics, treatment, and outcome of patients with ACS in
15 Europe and the Mediterranean basin in 2004. *Eur Heart J* 2006;27:2285-93.
16
17
- 18 8. Terkelsen CJ, Lassen JF, Norgaard BL, et al. Mortality rates in patients with ST-elevation
19 vs. non-ST-elevation acute myocardial infarction: observations from an unselected
20 cohort. *Eur Heart J* 2005;26:18-26.
21
22
- 23 9. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute
24 coronary syndromes in patients presenting without persistent ST-segment elevation: Task
25 Force for the Management of Acute Coronary Syndromes in Patients Presenting without
26 Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur*
27 *Heart J* 2016;37:267-315.
28
29
- 30 10. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute
31 myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*
32 2012;33:2569-619.
33
34
- 35 11. Kubica J. The optimal antiplatelet treatment in an emergency setting. *Folia Med*
36 *Copernicana* 2014;2:73-6.
37
38
- 39 12. Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors:
40 collaborative analysis on the role of platelet reactivity for risk stratification after
41 percutaneous coronary intervention. *Eur Heart J* 2015;36:1762-71.
42
43
- 44 13. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics,
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 and safety of the oral reversible P2Y₁₂ antagonist AZD6140 with aspirin in patients with
4 atherosclerosis: a double-blind comparison to clopidogrel with aspirin. *Eur Heart J*
5 2006;27:1038-47.
6
7
8
9
10 14. Varenhorst C, Eriksson N, Johansson Å, et al. Effect of genetic variations on ticagrelor
11 plasma levels and clinical outcomes. *Eur Heart J* 2015;36:1901-12.
12
13
14 15. Teng R, Mitchell P, Butler K. Effect of age and gender on pharmacokinetics and
15 pharmacodynamics of a single ticagrelor dose in healthy individuals. *Eur J Clin*
16 *Pharmacol* 2012;68:1175-82.
17
18
19
20 16. Teng R, Mitchell PD, Butler K. Lack of significant food effect on the pharmacokinetics
21 of ticagrelor in healthy volunteers. *J Clin Pharm Ther* 2012;37:464-8.
22
23
24 17. Husted SE, Storey RF, Bliden K, et al. Pharmacokinetics and pharmacodynamics of
25 ticagrelor in patients with stable coronary artery disease: results from the ONSET-
26 OFFSET and RESPOND studies. *Clin Pharmacokinet* 2012;51:397-409.
27
28
29
30 18. Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine decreases ticagrelor concentrations
31 but not its antiplatelet effects: a randomized trial in healthy volunteers. *Eur J Clin Invest*
32 2016;46:7-14.
33
34
35 19. Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor
36 exposure and action in patients with myocardial infarction: the randomized, double-blind,
37 placebo-controlled IMPRESSION trial. *Eur Heart J* 2016;37:245-52.
38
39
40 20. Kubica J, Kubica A, Jilma B, et al. Impact of morphine on antiplatelet effects of oral
41 P2Y₁₂ receptor inhibitors. *Int J Cardiol* 2016;215:201-8.
42
43
44
45 21. Adamski P, Ostrowska M, Sroka WD, et al. Does morphine administration affect
46 ticagrelor conversion to its active metabolite in patients with acute myocardial infarction?
47 A sub-analysis of the randomized, double-blind, placebo-controlled IMPRESSION trial.
48 *Folia Med Copernicana* 2015;3:100-6.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 22. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading
4 doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of
5 Platelet Inhibitor Drugs) primary PCI study. *J Am Coll Cardiol* 2013;61:1601-6.
6
7
8
9
10 23. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by
11 AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in
12 patients with acute coronary syndromes. *J Am Coll Cardiol* 2007;50:1852-6.
13
14
15
16 24. Laine M, Toesca R, Berbis J, et al. Platelet reactivity evaluated with the VASP assay
17 following ticagrelor loading dose in acute coronary syndrome patients undergoing
18 percutaneous coronary intervention. *Thromb Res* 2013;132:e15-8.
19
20
21
22
23 25. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with
24 acute coronary syndromes. *N Engl J Med* 2009;361:1045-57.
25
26
27
28 26. Kubica J, Adamski P, Ostrowska M, et al. Influence of Morphine on Pharmacokinetics
29 and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction
30 (IMPRESSION): study protocol for a randomized controlled trial. *Trials* 2015;16:198.
31
32
33
34
35
36

37 **Figure 1.** The PINPOINT study schema.

38
39
40 ASA: aspirin; LD: loading dose; NSTEMI: non-ST-elevation myocardial infarction; PCI:
41 percutaneous coronary intervention; PD: pharmacodynamics; PK: pharmacokinetics; STEMI:
42 ST-elevation myocardial infarction.
43
44
45

46
47 **Figure 2.** Platelet reactivity evaluation schedule for the PINPOINT study.

48
49
50 GP IIb/IIIa: glycoprotein IIb/IIIa; MEA: multiple electrode aggregometry; VASP:
51 vasodilator-stimulated phosphoprotein.
52
53
54
55
56
57
58
59
60




Figure 1. PINPOINT study schema.

ASA: aspirin; LD: loading dose; NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; PD: pharmacodynamics; PK: pharmacokinetics; STEMI: ST-elevation myocardial infarction.

254x190mm (96 x 96 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Platelet reactivity evaluation schedule for the PINPOINT study. GP IIb/IIIa: glycoprotein IIb/IIIa; MEA: multiple electrode aggregometry; VASP: vasodilator-stimulated phosphoprotein.

145x60mm (120 x 120 DPI)

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

Protocol for the PINPOINT study.

	Item No	Recommendation
✓ Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
✓ Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
✓ Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
✓ Study design	4	Present key elements of study design early in the paper
✓ Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
✓ Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
✓ Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
✓ Data sources/measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
✓ Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
✓ Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Comment [PA1]: Will be published in the main publication with final results of the study.

Comment [PA2]: Will be published in the main publication with final results of the study.

Results

✓	Participants	13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
✓	Descriptive data	14	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
✓	Outcome data	15	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion			
	Key results	18	Summarise key results with reference to study objectives
	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
	Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information			
✓	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

Comment [PA3]: Will be published in the main publication with final results of the study.

Comment [PA4]: Will be published in the main publication with final results of the study.

Comment [PA5]: Will be published in the main publication with final results of the study.

Comment [PA6]: Will be published in the main publication with final results of the study.

Comment [PA7]: Will be published in the main publication with final results of the study.

Comment [PA8]: Will be published in the main publication with final results of the study.

BMJ Open

Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single centre study



Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013218.R1
Article Type:	Protocol
Date Submitted by the Author:	02-Nov-2016
Complete List of Authors:	Adamski, Piotr; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Principles of Clinical Medicine Ostrowska, Małgorzata; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Principles of Clinical Medicine Sikora, Joanna; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Pharmacology and Therapy Obońska, Karolina; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Cardiology and Internal Medicine Buszko, Katarzyna; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Theoretical Foundations of Biomedical Science and Medical Informatics Krintus, Magdalena; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Laboratory Medicine Sypniewska, Grazyna; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Laboratory Medicine Marszał, Michał; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Medicinal Chemistry Kozinski, Marek; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Principles of Clinical Medicine Kubica, Jacek; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Cardiology and Internal Medicine
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Pharmacology and therapeutics
Keywords:	NSTEMI, pharmacodynamics, pharmacokinetics, STEMI, ticagrelor

SCHOLARONE™
Manuscripts

Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single centre study

Piotr Adamski,^{1†} Małgorzata Ostrowska,¹ Joanna Sikora,² Karolina Obońska,³ Katarzyna Buszko,⁴ Magdalena Krintus,⁵ Grażyna Sypniewska,⁵ Michał Piotr Marszałł,⁶ Marek Koziński,¹ Jacek Kubica³

¹Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

²Department of Pharmacology and Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

³Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁴Department of Theoretical Foundations of Biomedical Science and Medical Informatics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁵Department of Laboratory Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁶Department of Medicinal Chemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

† Corresponding author

Address for correspondence: Piotr Adamski, Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, 9 Skłodowskiej-Curie Street, 85-094 Bydgoszcz, Poland; Tel.: +48 52 5854023, Fax: +48 52 5854024; E-mail: piotr.adamski@wp.eu

Keywords: NSTEMI, pharmacodynamics, pharmacokinetics, STEMI, ticagrelor

Word count: 3229

ABSTRACT

Introduction

The most often applied classification of acute myocardial infarction (AMI) is based on the electrocardiographic findings and distinguishes ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). Epidemiology, clinical approach and early outcomes differ between patients with these two types of AMI. Ticagrelor is a P2Y₁₂ receptor inhibitor which is the first line treatment in both STEMI and NSTEMI patients. Available data suggest that STEMI diagnosis can be associated with lower plasma concentrations of ticagrelor in the first hours of AMI, but currently there are no studies directly comparing ticagrelor's pharmacokinetics or antiplatelet effect in STEMI and NSTEMI patients.

Methods and analysis

The PINPOINT study is a phase IV, single centre, investigator-initiated, prospective, observational study designed to compare pharmacokinetics and pharmacodynamics of ticagrelor in STEMI and NSTEMI patients designated to invasive strategy. Based on the internal pilot study, the trial is expected to include at least 23 patients with each AMI type. All subjects will receive 180 mg loading dose of ticagrelor. The primary end-point of the study is area under the plasma concentration-time curve ($AUC_{(0-6)}$) for ticagrelor for the first 6 hours after the loading dose. Secondary end-points include various pharmacokinetic features of ticagrelor and its active metabolite (AR-C124910XX), and evaluation of platelet reactivity by VASP assay and multiple electrode aggregometry. Blood samples for the pharmacokinetic and pharmacodynamic assessment will be obtained at pre-treatment, 30min, 1h, 2h, 3h, 4h, 6h and 12h post ticagrelor loading dose.

Ethics and dissemination

The study received approval from the Local Ethics Committee to conduct the study (Komisja Bioetyczna Uniwersytetu Mikołaja Kopernika w Toruniu przy Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy; approval reference number KB 617/2015). The study results will be disseminated through conference presentations and peer-reviewed journals.

Trial Registration: ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015)

INTRODUCTION

Background

Third Universal Definition of Myocardial Infarction recognizes five different types of myocardial infarction based on their pathomechanism or clinical cause.[1] However, a different classification is routinely applied in everyday practice to facilitate the immediate choice of treatment strategy in patients with acute myocardial infarction (AMI). This classification is based on the electrocardiographic findings and distinguishes ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI).[1]

Over the past years the incidence of STEMI has decreased, while the occurrence of NSTEMI has slightly increased, and currently STEMI and NSTEMI occur almost equally often.[2, 3] Short-term mortality is higher in STEMI patients, however the mortality rates become comparable or even higher in NSTEMI patients at long-term follow-up.[4-7]

In STEMI, which is usually caused by acute total occlusion of coronary artery, immediate primary percutaneous coronary intervention (PCI) is the mainstay of treatment.[8] In NSTEMI, the therapeutic strategy and its timing depends on the risk stratification.[7] Complementary to coronary revascularization, dual antiplatelet therapy consisting of aspirin on top of a P2Y12 receptor inhibitor remains the cornerstone of pharmacological treatment in AMI patients, including both STEMI and NSTEMI.[9] The importance of platelet P2Y12 receptor blockade in patients with AMI derives from the essential role exerted by platelet activation and aggregation in the pathophysiology of acute coronary syndromes (ACS).[10] Inadequate platelet inhibition during treatment with P2Y12 receptor inhibitors, defined as high platelet reactivity (HPR), is an important risk factor for stent thrombosis and can be associated with increased mortality.[11, 12] Therefore, effective and rapid suppression of platelet activation is pivotal in patients with AMI treated with PCI.

1
2
3 Ticagrelor is a reversible, oral P2Y₁₂ receptor inhibitor which is recommended as the
4 first line treatment both in STEMI and NSTEMI patients.[13, 14] Ticagrelor is characterized
5 by a linear pharmacokinetics and does not require hepatic metabolism to exert its antiplatelet
6 action. Nevertheless, it is extensively metabolised by hepatic CYP3A enzymes.[15] AR-
7 C124910XX is the major active metabolite of ticagrelor and it produces similar antiplatelet
8 effect as the parent drug. After oral ingestion of ticagrelor, AR-C124910XX quickly appears
9 in circulation and reaches approximately one third of ticagrelor plasma concentration.[15] The
10 remaining 9 of identified ticagrelor metabolites appear not to be clinically significant.
11 Noteworthy, it has been reported that platelet inhibition by ticagrelor and AR-C124910XX is
12 proportional to their plasma concentrations.[16]
13
14
15
16
17
18
19
20
21
22
23
24

25 **Rationale**

26
27 Impact of numerous clinical features on plasma concentration and pharmacodynamics
28 of ticagrelor has been inspected. Genetic effects, gender, age, concomitant food intake or
29 preloading with clopidogrel have at most minimal influence on pharmacokinetics of
30 ticagrelor, which does not translate into any clinically significant differences in the degree of
31 platelet inhibition.[17-20] On the other hand, morphine administration has been shown to
32 affect ticagrelor's pharmacokinetic profile as well as antiplatelet effect not only in healthy
33 volunteers, but also in AMI patients.[21-23] Negative impact of morphine on the intestinal
34 absorption has been proposed as an explanation for the observed interactions, while no
35 evidence was found that morphine affects ticagrelor conversion to its active metabolite.[22,
36 24] Moreover, STEMI diagnosis has also been postulated to affect ticagrelor
37 pharmacokinetics in AMI patients. Franchi et al. reported that ticagrelor exposure is
38 attenuated and delayed not only in STEMI patients receiving morphine, but also in opioid-
39 naive STEMI subjects.[25] This may indicate that morphine is not exclusively responsible for
40 the observed lower concentrations of ticagrelor in STEMI patients when compared with
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 healthy volunteers or stable coronary artery disease patients.[20, 25, 26] Additionally,
4
5 multiple regression analysis of data obtained in the randomized IMPRESSION study
6
7 (Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients
8
9 with Acute Myocardial Infarction) suggests that clinical presentation as STEMI when
10
11 compared with NSTEMI is independently associated with lower plasma concentrations of
12
13 ticagrelor.[22]
14

15
16 Even though ticagrelor shows more potent and prompt platelet inhibition than
17
18 clopidogrel, it still fails to provide a desired antiplatelet effect in all STEMI patients during
19
20 the first hours after the loading dose (LD). At 2 hours after ticagrelor LD up to 60% of
21
22 STEMI patients may still suffer from inadequate platelet inhibition.[22, 25, 27] Data on the
23
24 proportion of NSTEMI patients loaded with ticagrelor who are at risk of HPR during peri-PCI
25
26 period is sparse, however as expected ticagrelor has been shown to provide stronger platelet
27
28 blockade than clopidogrel in this clinical setting.[28] Solely pharmacodynamic study by Laine
29
30 et al. reported that platelet reactivity assessed with the platelet vasodilator-stimulated
31
32 phosphoprotein (VASP) assay after administration of a 180 mg ticagrelor LD was not uniform
33
34 among ACS patients, but when grouped by ACS type (STEMI, NSTEMI and unstable angina)
35
36 it appeared to be similar ($p=0.9$). However, the authors assessed the antiplatelet effect of
37
38 ticagrelor only once in each patient and the time of blood sampling differed substantially
39
40 among trial participants. Additionally, blood samples for pharmacodynamic evaluation were
41
42 obtained between 6 and 24 hours after ticagrelor LD, leaving the first crucial hours after PCI
43
44 not covered by the analysis.[29]
45
46
47
48

49
50 Although mechanistic studies are lacking, diminished plasma concentration of
51
52 ticagrelor after LD observed in STEMI patients is most likely related to worse bioavailability
53
54 of ticagrelor in this setting. Apart from morphine administration, other factors also may
55
56 contribute to reduced gastrointestinal uptake of ticagrelor in STEMI. Adrenergic activation,
57
58
59
60

1
2
3 decreased cardiac output, hemodynamic instability and vasoconstriction of peripheral arteries,
4 more frequently observed in STEMI patients, lead to selective shunting of blood in order to
5 maintain sufficient perfusion of vital organs.[30, 31] This chain of events eventually may
6
7 cause intestinal hypoperfusion, which together with emesis potentially could explain poorer
8
9 absorption of oral agents, including ticagrelor, in STEMI patients. Usually, NSTEMI course
10
11 is less dramatic, but whether significant impairment of ticagrelor absorption with subsequent
12
13 inadequate platelet blockade occurs in these patients, remain unknown.
14
15
16
17

18
19 The Platelet Inhibition and Patient Outcomes (PLATO) study has shown a remarkable
20
21 reduction in cardiovascular events and all-cause mortality among ACS patients treated with
22
23 ticagrelor compared with those receiving clopidogrel. This superiority was demonstrated in
24
25 most of the analysed subgroups, including patients with STEMI and NSTEMI.[32]
26
27 Nevertheless, epidemiology, clinical approach and early outcomes differ between patients
28
29 with these two types of AMI, while recommended dosing regimens of ticagrelor are identical
30
31 in both clinical settings.[7, 8]
32
33

34
35 Currently, there are no data on direct comparison of ticagrelor's pharmacokinetics in
36
37 the mentioned types of AMI, while STEMI patients may be at risk of having lower ticagrelor
38
39 plasma concentrations in the most crucial time during the early hours of AMI treatment.[22]
40
41 Similarly, potential differences in ticagrelor's antiplatelet action between STEMI and
42
43 NSTEMI have not been defined yet. Therefore, we decided to verify whether
44
45 pharmacokinetics and pharmacodynamics of ticagrelor differ between STEMI and NSTEMI
46
47 patients. The Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI
48
49 and NSTEMI Patients (PINPOINT) study is expected to provide a valuable insight into our
50
51 knowledge regarding modern treatment of AMI patients.
52
53
54

55 **METHODS AND ANALYSIS**

56 57 58 **Study objectives**

1
2
3 The PINPOINT study is designed to compare pharmacokinetics and
4 pharmacodynamics of ticagrelor and its active metabolite (AR-C124910XX) in patients with
5 STEMI and NSTEMI designated to invasive strategy.
6
7
8
9

10 **Study design**

11
12 The PINPOINT study is a phase IV, single centre, investigator-initiated, prospective,
13 observational, pharmacokinetic-pharmacodynamic study. After admission to the study centre
14 (Cardiology Clinic, Dr. A. Jurasz University Hospital, Bydgoszcz, Poland) and confirmation
15 of STEMI or NSTEMI diagnosis according to the Third Universal Definition of Myocardial
16 Infarction,[1] patients will be screened for eligibility for the study. Before any study specific
17 procedure, each patient will provide a written informed consent to participate in the trial. All
18 included patients will immediately receive orally a 300 mg LD of plain aspirin in integral
19 tablets and a 180 mg LD of ticagrelor in integral tablets with 250 mL of tap water.
20 Subsequently, all patients will promptly undergo a coronary angiography followed by PCI, if
21 required. Blood samples for pharmacokinetic and pharmacodynamic assessment will be
22 drawn at eight predefined time points according to the blood sampling schedule already used
23 at our site in a previous study (pre-treatment baseline, 30min, 1h, 2h, 3h, 4h, 6h and 12h post
24 ticagrelor LD - as shown in Figure 1).[33]
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 All enrolled patients with the initial AMI diagnosis not confirmed will be excluded
42 from the primary analysis. Patients qualified for urgent CABG within the blood sampling
43 period also will not be included in the analysis. All study participants not receiving PCI will
44 be reported.
45
46
47
48
49

50 **Study population**

51
52 The study population will include consecutive adult, male or non-pregnant female,
53 P2Y12 receptor inhibitor-naive STEMI and NSTEMI patients, designated to invasive
54 strategy. Full list of inclusion and exclusion criteria are presented in Table 1.
55
56
57
58
59
60

Table 1. Inclusion and exclusion criteria of the PINPOINT study.

Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none"> • provision of informed consent prior to any study specific procedure • diagnosis of STEMI or NSTEMI • male or non-pregnant female, 18 years old and older • provision of informed consent for angiography and PCI 	<ul style="list-style-type: none"> • treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrolment • hypersensitivity to ticagrelor • current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin • active bleeding • history of intracranial haemorrhage • fibrinolytic treatment during the index event • recent gastrointestinal bleeding (within 30 days) • history of coagulation disorders • history of moderate or severe hepatic impairment • history of major surgery or severe trauma (within 3 months) • second or third degree atrioventricular block during screening for eligibility • patient required dialysis • manifest infection or inflammatory state • Killip class III or IV during screening for eligibility • respiratory failure • current therapy with strong CYP3A inhibitors or strong CYP3A inducers

NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention;

STEMI: ST-elevation myocardial infarction.

Blood sample processing

Blood samples for pharmacokinetic and pharmacodynamic evaluation will be obtained using a venous catheter (18G) inserted into a forearm vein at eight prespecified time-points

1
2
3 (before ticagrelor LD, 30min, 1h, 2h, 3h, 4h, 6h and 12h post ticagrelor LD - Figure 1).
4

5 Venous blood for the pharmacokinetic evaluation will be collected into lithium-
6 heparin vacuum test-tubes. Immediately after collection, each sample will be placed on dry
7 ice and will be transferred to the central laboratory. Subsequently, within 20 minutes from
8 collection, the blood will be centrifuged at 1500 g for 12 minutes at 4°C. Within 10 minutes
9 post-centrifugation, obtained plasma samples will be stored at temperature below -60°C until
10 analyzed.
11

12 Venous blood for the assessment of pharmacodynamics with VASP assay and multiple
13 electrode aggregometry (MEA) will be collected into trisodium citrate and hirudin vacuum
14 test-tubes, respectively. The first 3-5 mL of blood will be discarded to avoid spontaneous
15 platelet activation. Pharmacodynamic analysis will be performed for each sample within 24h
16 and 60min from blood collection for VASP and MEA, respectively.
17

18 **Assessment of pharmacokinetics**

19 Blood plasma concentrations of ticagrelor and AR-C124910XX in samples obtained at
20 all eight predefined time points (Figure 1) will be evaluated using liquid chromatography
21 mass spectrometry coupled with tandem mass spectrometry, as previously described.[22, 34]
22 Briefly, ticagrelor and AR-C124910XX will be extracted using 4°C methanol solution
23 containing [2H7]ticagrelor internal standard (TM-ALS-13-226-P1, ALSACHIM, France),
24 while calibration curves will be obtained using ticagrelor (SVI-ALS-13-146, ALSACHIM,
25 France) and AR-C124910XX (TM-ALS-13-193-P1, ALSACHIM, France) standards.
26 Analysis will be performed using the Shimadzu UPLC Nexera X2 system consisting of LC-
27 30AD pumps, SIL-30AC Autosampler, CTO-20AC column oven, FCV-20-AH2 valve unit,
28 and DGU-20A5R degasser coupled with Shimadzu 8030 ESI-QqQ mass spectrometer. Lower
29 limits of quantification are 4.69 ng/mL for both ticagrelor and AR-C124910XX.
30

31 **Assessment of pharmacodynamics**

1
2
3 Platelet VASP assay (Biocytex, Inc., Marseille, France) will be applied to all study
4 participants at all predefined time points. MEA (Roche Diagnostics International Ltd.,
5 Rotkreuz, Switzerland) will be used at all predefined time points (Figure 1) for all study
6 participants with the exception of those treated with glycoprotein IIb/IIIa (GP IIb/IIIa)
7 receptor inhibitors as this therapy may affect the results of platelet reactivity assessment with
8 MEA (Figure 2). Pharmacodynamic assessment with VASP and MEA will be performed
9 according to the manufacturers' instructions, as previously described.[35, 36] HPR will be
10 defined as platelet reactivity index (PRI) >50% and area under the aggregation curve >46
11 units, when evaluated with VASP and MEA, respectively.[37]
12
13
14
15
16
17
18
19
20
21
22
23

24 **Treatment**

25
26 All patients included in the trial will be treated according to the current European
27 Society of Cardiology (ESC) guidelines.[7, 8, 38] Standard therapy will include aspirin,
28 ticagrelor, beta-blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin
29 II receptor blockers, if not contraindicated. Morphine will be used at the discretion of the
30 ambulance staff and the attending physician. The type of implanted stent and the choice of the
31 access site for the coronary invasive procedure (radial or femoral) will be at the discretion of
32 the operator. During the periprocedural period, all study participants will receive
33 unfractionated heparin in body weight adjusted dose according to the ESC
34 recommendations.[7, 8, 38] Administration of GP IIb/IIIa receptor inhibitors will be restricted
35 only to bailout situations. Interventional cardiologists will be encouraged to use manual
36 thrombectomy in case of visible thrombus.
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Study endpoints**

51
52 The primary end-point of the study is area under the plasma concentration-time curve
53 (AUC₍₀₋₆₎) for ticagrelor for the first 6 hours after LD of ticagrelor. Secondary end-points
54 include AUC₍₀₋₆₎ for AR-C124910XX, area under the plasma concentration-time curve
55
56
57
58
59
60

(AUC₍₀₋₁₂₎) for ticagrelor for the first 12 hours after LD of ticagrelor, AUC₍₀₋₁₂₎ for AR-C124910XX, maximum concentration (C_{max}) of ticagrelor and AR-C124910XX, time to maximum concentration (t_{max}) for ticagrelor and AR-C124910XX, PRI assessed by the VASP assay, platelet reactivity assessed by MEA, percentage of patients with HPR after ticagrelor LD assessed with the VASP assay and MEA, time to reach platelet reactivity below the cut-off value for HPR evaluated with the VASP assay and MEA.

Statistical analysis

The continuous variables in the both study groups will be compared by t-test for normally distributed values as assessed by Kolmogorov-Smirnov test. Otherwise, the Mann-Whitney U test will be used. Proportions will be compared by the chi-square test when appropriate. A single linear regression analysis will be performed and will be followed by a multiple regression analysis in case any variables are found to significantly affect the study primary end-point. Pharmacokinetic calculations and plots will be made using dedicated software.

Determination of sample size

Since there is no reference study comparing pharmacokinetics of ticagrelor in STEMI and NSTEMI patients, we decided to perform an internal pilot study of at least 15 patients with each type of AMI for estimating the final sample size. Eventually, the pilot study population comprised of 45 patients (15 with NSTEMI and 30 with STEMI). This included all consecutively enrolled study participants who entered the trial until the minimum planned number of patients was reached in the less numerous group (NSTEMI).

The means and standard deviations of AUC₍₀₋₆₎ for ticagrelor in the first 30 STEMI patients and 15 NSTEMI patients were 2382 ± 2282 and 6406 ± 4082 ng*h/ml, respectively. Based on these results and assuming a two-sided alpha value of 0.05, we calculated, using the t-test for independent variables, that enrolment of at least 23 patients in each study arm would

1
2
3 provide a 95% power to demonstrate a significant difference in $AUC_{(0-6)}$ for ticagrelor
4
5 between patients with different type of MI.
6
7

8 **Study limitations**

9
10 Several limitations of our study have to be acknowledged. First, the anticipated trial
11 population will not be sufficient to evaluate clinical end-points and most likely to perform
12 subgroup analyses. Second, patients receiving morphine are not excluded from the study,
13 which may result in the baseline characteristics differences between the examined groups.
14
15 Third, morphine is used at the discretion of the paramedics or the attending physicians,
16 although we encourage the medical staff to administer a standardized dose of 5 mg
17 intravenously, if required in any potential or actual study participant. On the other hand, even
18 though it may be perceived as a limitation, this will enable us to obtain a real life data and will
19 not create artificially selected population.
20
21
22
23
24
25
26
27
28
29
30

31 **ETHICS AND DISSEMINATION**

32 **Ethics**

33
34 The study will be conducted in accordance with the principles contained in the
35 Declaration of Helsinki and Good Clinical Practice guidelines. The study received a
36 favourable ethical opinion and approval from the Local Ethics Committee to conduct the
37 study (Komisja Bioetyczna Uniwersytetu Mikołaja Kopernika w Toruniu przy Collegium
38 Medicum im. Ludwika Rydygiera w Bydgoszczy; study approval reference number KB
39 617/2015). Each patient will provide a written informed consent to participate in the study.
40
41
42
43
44
45
46
47
48
49

50 **Safety**

51
52 The following safety endpoints will be recorded during the blood sampling period: all-
53 cause death, recurrent myocardial infarction according to the Third Universal Definition of
54 Myocardial Infarction, stroke, and transient ischaemic attack according to definitions used in
55
56
57
58
59
60

the PLATO trial, definite or probable stent thrombosis according to the Academic Research Consortium criteria, minor and major bleedings according to the TIMI (thrombolysis in myocardial infarction) criteria, dyspnea adverse events according to criteria used in the PLATO trial, bradyarrhythmic events according to criteria used in the PLATO trial.

Present status

The approval of the Local Ethic Committee was obtained on September 29, 2015. On November 9, 2015 the PINPOINT study was registered on ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT02602444). The first patient was enrolled in November 2015. The baseline characteristics of patients included in the pilot study are presented in Table 2.

Table 2. Baseline characteristics of patients included in the internal pilot study.

	STEMI (n=30)	NSTEMI (n=15)	p value
Age [years]	62.3 ± 8.8	63.9 ± 9.7	0.51
Age ≥70 years	6 (20.0%)	4 (26.7%)	0.89
Female	6 (20.0%)	5 (33.3%)	0.53
BMI [kg/m ²]	28.6 ± 4.1	27.8 ± 4.2	0.76
Hypertension	10 (33.3%)	10 (66.7%)	0.036
Diabetes mellitus	6 (20.0%)	2 (13.3%)	0.89
Dyslipidaemia	27 (90.0%)	14 (93.3%)	0.85
Current smoker	13 (43.3%)	5 (33.3%)	0.52
Prior MI	0	2 (13.3%)	n/a
Prior PCI	2 (6.7%)	3 (20.0%)	0.4
Prior CABG	0	0	n/a
Congestive heart failure	0	0	n/a
Nonhaemorrhagic stroke	0	0	n/a
Peripheral arterial disease	1 (3.3%)	2 (13.3%)	0.21
Chronic renal disease	0	0	n/a
Chronic obstructive pulmonary	0	0	n/a

disease			
Gout	1 (3.3%)	1 (6.7%)	n/a
Morphine use during current MI	17 (56.7%)	6 (40.0%)	0.29

BMI: body mass index; CABG: coronary artery bypass surgery; MI: myocardial infarction; n/a: not available; NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction. Data are shown as mean \pm standard deviation or number (%).

Dissemination of results

Results of the PINPOINT study will be disseminated through conference presentations and peer-reviewed journals. The results will also be made available through study record website at ClinicalTrials.gov.

SUMMARY

Is it unknown whether ticagrelor's pharmacokinetic profile and antiplatelet effects are uniform in STEMI and NSTEMI patients, who are a very heterogeneous population. The PINPOINT trial is expected to be the first study to elucidate whether diagnosis of STEMI is associated with poorer absorption and subsequently weaker antiplatelet action of ticagrelor when compared with NSTEMI patients.

Contributors

JK and PA conceived the study. JK and PA wrote the study protocol with consultation from MO, JS, KO, KB, MKr, GS, MM and MKo. Subsequently JK, PA, MO, JS, KO, KB, MKr, GS, MM and MKo revised the manuscript critically for important intellectual content. All the authors read and approved the final manuscript.

Competing interests

Dr. Jacek Kubica received a consulting fee from AstraZeneca. Dr. Marek Koziński received honoraria for lectures from AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Funding

The study is funded by Collegium Medicum of Nicolaus Copernicus University and did not receive any external funding.

Ethics approval

Local Ethics Committee: Komisja Bioetyczna Uniwersytetu Mikołaja Kopernika w Toruniu przy Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy (study approval reference number: KB 617/2015).

References

1. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Eur Heart J* 2012;33:2551-67.
2. McManus DD, Gore J, Yarzebski J, et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. *Am J Med* 2011;124:40-7.
3. Gierlotka M, Zdrojewski T, Wojtyniak B, et al. Incidence, treatment, in-hospital mortality and one-year outcomes of acute myocardial infarction in Poland in 2009-2012-nationwide AMI-PL database. *Kardiol Pol* 2015;73:142-58.
4. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. *JAMA* 1999;281:707-13.
5. Mandelzweig L, Battler A, Boyko V, et al. The Second Euro Heart Survey on Acute Coronary Syndromes: characteristics, treatment, and outcome of patients with ACS in

- 1
2
3 Europe and the Mediterranean basin in 2004. *Eur Heart J* 2006;27:2285-93.
- 4
5 6. Terkelsen CJ, Lassen JF, Norgaard BL, et al. Mortality rates in patients with ST-elevation
6
7 vs. non-ST-elevation acute myocardial infarction: observations from an unselected
8
9 cohort. *Eur Heart J* 2005;26:18-26.
- 10
11 7. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute
12
13 coronary syndromes in patients presenting without persistent ST-segment elevation: Task
14
15 Force for the Management of Acute Coronary Syndromes in Patients Presenting without
16
17 Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur*
18
19 *Heart J* 2016;37:267-315.
- 20
21 8. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute
22
23 myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*
24
25 2012;33:2569-619.
- 26
27 9. Adamski P, Adamska U, Ostrowska M, et al. New directions for pharmacotherapy in the
28
29 treatment of acute coronary syndrome. *Expert Opin Pharmacother* Published Online
30
31 First: 10 October 2016. doi: 10.1080/14656566.2016.1241234
- 32
33 10. Kubica J. The optimal antiplatelet treatment in an emergency setting. *Folia Med*
34
35 *Copernicana* 2014;2:73-6.
- 36
37 11. Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors:
38
39 collaborative analysis on the role of platelet reactivity for risk stratification after
40
41 percutaneous coronary intervention. *Eur Heart J* 2015;36:1762-71.
- 42
43 12. Winter MP, Koziński M, Kubica J, et al. Personalized antiplatelet therapy with P2Y12
44
45 receptor inhibitors: benefits and pitfalls. *Postepy Kardiol Interwencyjnej* 2015;11:259-80.
- 46
47 13. Navarese EP, Buffon A, Kozinski M, et al. A critical overview on ticagrelor in acute
48
49 coronary syndromes. *QJM* 2013;106:105-15.
- 50
51 14. Adamski P, Koziński M, Ostrowska M, et al. Overview of pleiotropic effects of platelet
52
53
54
55
56
57
58
59
60

- 1
2
3 P2Y12 receptor inhibitors. *Thromb Haemost* 2014;112:224-42.
- 4
5 15. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and
6
7 excretion of ticagrelor in healthy subjects. *Drug Metab Dispos* 2010;38:1514-21.
- 8
9
10 16. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics,
11
12 and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with
13
14 atherosclerosis: a double-blind comparison to clopidogrel with aspirin. *Eur Heart J*
15
16 2006;27:1038-47.
- 17
18
19 17. Varenhorst C, Eriksson N, Johansson Å, et al. Effect of genetic variations on ticagrelor
20
21 plasma levels and clinical outcomes. *Eur Heart J* 2015;36:1901-12.
- 22
23 18. Teng R, Mitchell P, Butler K. Effect of age and gender on pharmacokinetics and
24
25 pharmacodynamics of a single ticagrelor dose in healthy individuals. *Eur J Clin*
26
27 *Pharmacol* 2012;68:1175-82.
- 28
29
30 19. Teng R, Mitchell PD, Butler K. Lack of significant food effect on the pharmacokinetics
31
32 of ticagrelor in healthy volunteers. *J Clin Pharm Ther* 2012;37:464-8.
- 33
34 20. Husted SE, Storey RF, Bliden K, et al. Pharmacokinetics and pharmacodynamics of
35
36 ticagrelor in patients with stable coronary artery disease: results from the ONSET-
37
38 OFFSET and RESPOND studies. *Clin Pharmacokinet* 2012;51:397-409.
- 39
40
41 21. Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine decreases ticagrelor concentrations
42
43 but not its antiplatelet effects: a randomized trial in healthy volunteers. *Eur J Clin Invest*
44
45 2016;46:7-14.
- 46
47
48 22. Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor
49
50 exposure and action in patients with myocardial infarction: the randomized, double-blind,
51
52 placebo-controlled IMPRESSION trial. *Eur Heart J* 2016;37:245-52.
- 53
54
55 23. Kubica J, Kubica A, Jilma B, et al. Impact of morphine on antiplatelet effects of oral
56
57 P2Y12 receptor inhibitors. *Int J Cardiol* 2016;215:201-8.
- 58
59
60

- 1
2
3 24. Adamski P, Ostrowska M, Sroka WD, et al. Does morphine administration affect
4 ticagrelor conversion to its active metabolite in patients with acute myocardial infarction?
5 A sub-analysis of the randomized, double-blind, placebo-controlled IMPRESSION trial.
6
7 *Folia Med Copernicana* 2015;3:100-6.
8
9
10
11 25. Franchi F, Rollini F, Cho JR, et al. Impact of Escalating Loading Dose Regimens of
12 Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing
13 Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized
14 Pharmacokinetic and Pharmacodynamic Investigation. *JACC Cardiovasc Interv*
15 2015;8:1457-67.
16
17
18 26. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single
19 ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in
20 healthy subjects. *Eur J Clin Pharmacol* 2010;66:487-96.
21
22
23 27. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading
24 doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of
25 Platelet Inhibitor Drugs) primary PCI study. *J Am Coll Cardiol* 2013;61:1601-6.
26
27
28 28. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by
29 AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in
30 patients with acute coronary syndromes. *J Am Coll Cardiol* 2007;50:1852-6.
31
32
33 29. Laine M, Toesca R, Berbis J, et al. Platelet reactivity evaluated with the VASP assay
34 following ticagrelor loading dose in acute coronary syndrome patients undergoing
35 percutaneous coronary intervention. *Thromb Res* 2013;132:e15-8.
36
37
38 30. Heestermans AA, van Werkum JW, Taubert D, et al. Impaired bioavailability of
39 clopidogrel in patients with a ST-segment elevation myocardial infarction. *Thromb Res*
40 2008;122:776-81.
41
42
43 31. Kubica J, Kozinski M, Navarese EP, et al. Cangrelor: an emerging therapeutic option for
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 patients with coronary artery disease. *Curr Med Res Opin* 2014;30:813-28.
- 4
5 32. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with
6 acute coronary syndromes. *N Engl J Med* 2009;361:1045-57.
- 7
8
9 33. Kubica J, Adamski P, Ostrowska M, et al. Influence of Morphine on Pharmacokinetics
10 and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction
11 (IMPRESSIO): study protocol for a randomized controlled trial. *Trials* 2015;16:198.
- 12
13
14 34. Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma
15 samples by liquid chromatography and mass spectrometry. *J Chromatogr B Analyt*
16 *Technol Biomed Life Sci* 2010;878:2299-306.
- 17
18
19 35. Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of
20 antiplatelet effect of clopidogrel in patients after myocardial infarction. *Eur J Pharmacol*
21 2014;742:47-54.
- 22
23
24 36. Koziński M, Obońska K, Stankowska K, et al. Prasugrel overcomes high on-clopidogrel
25 platelet reactivity in the acute phase of acute coronary syndrome and maintains its
26 antiplatelet potency at 30-day follow-up. *Cardiol J* 2014;21:547-56.
- 27
28
29 37. Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role of platelet
30 function testing in patients undergoing percutaneous coronary intervention. *Eur Heart J*
31 2014;35:209-15.
- 32
33
34 38. Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines
35 on myocardial revascularization: The Task Force on Myocardial Revascularization of the
36 European Society of Cardiology (ESC) and the European Association for Cardio-
37 Thoracic Surgery (EACTS): Developed with the special contribution of the European
38 Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J*
39 2014;35:2541-619.
- 40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure 1.** The PINPOINT study schema.
4

5
6 ASA: aspirin; LD: loading dose; NSTEMI: non-ST-elevation myocardial infarction; PCI:
7
8 percutaneous coronary intervention; PD: pharmacodynamics; PK: pharmacokinetics; STEMI:
9
10 ST-elevation myocardial infarction.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **Figure 2.** Platelet reactivity evaluation schedule for the PINPOINT study.
4

5
6 GP IIb/IIIa: glycoprotein IIb/IIIa; MEA: multiple electrode aggregometry; VASP:

7
8 vasodilator-stimulated phosphoprotein.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1. PINPOINT study schema.

ASA: aspirin; LD: loading dose; NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; PD: pharmacodynamics; PK: pharmacokinetics; STEMI: ST-elevation myocardial infarction.

254x190mm (300 x 300 DPI)




Figure 2. Platelet reactivity evaluation schedule for the PINPOINT study.
 GP IIb/IIIa: glycoprotein IIb/IIIa; MEA: multiple electrode aggregometry; VASP: vasodilator-stimulated phosphoprotein.

254x190mm (300 x 300 DPI)

Preview Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

Protocol for the PINPOINT study.

	Item No	Recommendation
✓ Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
✓ Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
✓ Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
✓ Study design	4	Present key elements of study design early in the paper
✓ Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
✓ Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
✓ Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
✓ Data sources/measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
✓ Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
✓ Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Comment [PA1]: Will be published in the main publication with final results of the study.

Comment [PA2]: Will be published in the main publication with final results of the study.

Results

✓ Participants	13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
✓ Descriptive data	14	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
✓ Outcome data	15	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		
✓ Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

Comment [PA3]: Will be published in the main publication with final results of the study.

Comment [PA4]: Will be published in the main publication with final results of the study.

Comment [PA5]: Will be published in the main publication with final results of the study.

Comment [PA6]: Will be published in the main publication with final results of the study.

Comment [PA7]: Will be published in the main publication with final results of the study.

Comment [PA8]: Will be published in the main publication with final results of the study.

BMJ Open

Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single centre study



Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013218.R2
Article Type:	Protocol
Date Submitted by the Author:	17-Jan-2017
Complete List of Authors:	Adamski, Piotr; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Principles of Clinical Medicine Ostrowska, Małgorzata; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Principles of Clinical Medicine Sikora, Joanna; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Pharmacology and Therapy Obońska, Karolina; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Cardiology and Internal Medicine Buszko, Katarzyna; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Theoretical Foundations of Biomedical Science and Medical Informatics Krintus, Magdalena; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Laboratory Medicine Sypniewska, Grazyna; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Laboratory Medicine Marszał, Michał; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Medicinal Chemistry Kozinski, Marek; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Principles of Clinical Medicine Kubica, Jacek; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Cardiology and Internal Medicine
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Pharmacology and therapeutics
Keywords:	NSTEMI, pharmacodynamics, pharmacokinetics, STEMI, ticagrelor

SCHOLARONE™
Manuscripts

Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single centre study

Piotr Adamski,^{1†} Małgorzata Ostrowska,¹ Joanna Sikora,² Karolina Obońska,³ Katarzyna Buszko,⁴ Magdalena Krintus,⁵ Grażyna Sypniewska,⁵ Michał Piotr Marszałł,⁶ Marek Koziński,¹ Jacek Kubica³

¹Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

²Department of Pharmacology and Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

³Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁴Department of Theoretical Foundations of Biomedical Science and Medical Informatics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁵Department of Laboratory Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁶Department of Medicinal Chemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

† Corresponding author

Address for correspondence: Piotr Adamski, Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, 9 Skłodowskiej-Curie Street, 85-094 Bydgoszcz, Poland; Tel.: +48 52 5854023, Fax: +48 52 5854024; E-mail: piotr.adamski@wp.eu

Keywords: NSTEMI, pharmacodynamics, pharmacokinetics, STEMI, ticagrelor

Word count: 3097

ABSTRACT

Introduction

The most often applied classification of acute myocardial infarction (AMI) is based on the electrocardiographic findings and distinguishes ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). Epidemiology, clinical approach and early outcomes differ between patients with these two types of AMI. Ticagrelor is a P2Y₁₂ receptor inhibitor which is the first line treatment in both STEMI and NSTEMI patients. Available data suggest that STEMI diagnosis can be associated with lower plasma concentrations of ticagrelor in the first hours of AMI, but currently there are no studies directly comparing ticagrelor's pharmacokinetics or antiplatelet effect in STEMI and NSTEMI patients.

Methods and analysis

The PINPOINT study is a phase IV, single centre, investigator-initiated, prospective, observational study designed to compare pharmacokinetics and pharmacodynamics of ticagrelor in STEMI and NSTEMI patients designated to invasive strategy. Based on the internal pilot study, the trial is expected to include at least 23 patients with each AMI type. All subjects will receive 180 mg loading dose of ticagrelor. The primary end-point of the study is area under the plasma concentration-time curve ($AUC_{(0-6)}$) for ticagrelor for the first 6 hours after the loading dose. Secondary end-points include various pharmacokinetic features of ticagrelor and its active metabolite (AR-C124910XX), and evaluation of platelet reactivity by VASP assay and multiple electrode aggregometry. Blood samples for the pharmacokinetic and pharmacodynamic assessment will be obtained at pre-treatment, 30min, 1h, 2h, 3h, 4h, 6h and 12h post ticagrelor loading dose.

Ethics and dissemination

The study received approval from the Local Ethics Committee to conduct the study (Komisja Bioetyczna Uniwersytetu Mikołaja Kopernika w Toruniu przy Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy; approval reference number KB 617/2015). The study results will be disseminated through conference presentations and peer-reviewed journals.

Trial Registration: ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015)

STRENGTHS AND LIMITATIONS

- This is the first study to provide prospective head-to-head comparison of ticagrelor pharmacokinetics and pharmacodynamics between STEMI and NSTEMI patients designated to invasive strategy.
- Plasma concentrations of ticagrelor and its active metabolite will be assessed with liquid chromatography mass spectrometry coupled with tandem mass spectrometry.
- Antiplatelet effect of ticagrelor will be evaluated with two commonly recognized methods: vasodilator-stimulated phosphoprotein (VASP) assay and multiple electrode aggregometry.
- This is purely pharmacokinetic/pharmacodynamic study, thus unfortunately the anticipated trial population most likely will not be sufficient to evaluate clinical endpoints or to perform subgroup analyses.
- Patients receiving morphine are not excluded from the study, which may result in the baseline characteristics differences between the examined groups, but this will enable us to obtain a real life data and will not create artificially selected population.

INTRODUCTION

Background

Classification of acute myocardial infarction (AMI) routinely applied in everyday practice to facilitate the choice of treatment strategy is based on the electrocardiographic findings, and distinguishes ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI).[1]

In STEMI, which is usually caused by acute total occlusion of coronary artery, immediate primary percutaneous coronary intervention (PCI) is the mainstay of treatment.[2] In NSTEMI, the therapeutic strategy and its timing depends on the risk stratification.[3] Complementary to coronary revascularization, dual antiplatelet therapy consisting of aspirin on top of a P2Y12 receptor inhibitor remains the cornerstone of pharmacological treatment in AMI patients, including both STEMI and NSTEMI.[4, 5] Inadequate platelet inhibition during treatment with P2Y12 receptor inhibitors, defined as high platelet reactivity (HPR), is an important risk factor for stent thrombosis and can be associated with increased mortality.[6, 7] Therefore, effective and rapid suppression of platelet activation is pivotal in patients with AMI treated with PCI.

Ticagrelor is a reversible, oral P2Y12 receptor inhibitor which is recommended as the first line treatment both in STEMI and NSTEMI patients.[8, 9] Ticagrelor is characterized by a linear pharmacokinetics and does not require hepatic metabolism to exert its antiplatelet action. Nevertheless, it is extensively metabolised by hepatic CYP3A enzymes.[10] AR-C124910XX is the major active metabolite of ticagrelor and it produces similar antiplatelet effect as the parent drug. After oral ingestion of ticagrelor, AR-C124910XX quickly appears in circulation and reaches approximately one third of ticagrelor plasma concentration.[10] The remaining 9 of identified ticagrelor metabolites appear not to be clinically significant.

1
2
3 Noteworthy, it has been reported that platelet inhibition by ticagrelor and AR-C124910XX is
4
5 proportional to their plasma concentrations.[11]
6

7 8 **Rationale**

9
10 Impact of numerous clinical features on plasma concentration and pharmacodynamics
11
12 of ticagrelor has been inspected. Genetic effects, gender, age, concomitant food intake or
13
14 preloading with clopidogrel have at most minimal influence on pharmacokinetics of
15
16 ticagrelor, which does not translate into any clinically significant differences in the degree of
17
18 platelet inhibition.[12-15] On the other hand, morphine administration has been shown to
19
20 affect ticagrelor's pharmacokinetic profile as well as antiplatelet effect not only in healthy
21
22 volunteers, but also in AMI patients.[16-18] Negative impact of morphine on the intestinal
23
24 absorption has been proposed as an explanation for the observed interactions, while no
25
26 evidence was found that morphine affects ticagrelor conversion to its active metabolite.[18,
27
28 19] Importantly, STEMI diagnosis has also been postulated to affect ticagrelor
29
30 pharmacokinetics in AMI patients. Franchi et al. reported that ticagrelor exposure is
31
32 attenuated and delayed not only in STEMI patients receiving morphine, but also in opioid-
33
34 naive STEMI subjects.[20] This may indicate that morphine is not exclusively responsible for
35
36 the observed lower concentrations of ticagrelor in STEMI patients when compared with
37
38 healthy volunteers or stable coronary artery disease patients.[15, 20, 21] Moreover, sub-
39
40 analyses of two pharmacokinetic/pharmacodynamic trials suggest that clinical presentation as
41
42 STEMI when compared with NSTEMI is independently associated with lower plasma
43
44 concentrations of ticagrelor.[18, 22]
45
46
47

48
49 Although mechanistic studies are lacking, diminished plasma concentration of
50
51 ticagrelor after loading dose (LD) observed in STEMI patients is most likely related to worse
52
53 bioavailability of ticagrelor in this setting. Adrenergic activation, decreased cardiac output,
54
55 hemodynamic instability and vasoconstriction of peripheral arteries, more frequently observed
56
57
58
59
60

1
2
3 in STEMI patients, lead to selective shunting of blood in order to maintain sufficient
4 perfusion of vital organs.[23, 24] This chain of events eventually may cause intestinal
5 hypoperfusion, which together with emesis potentially could explain poorer absorption of oral
6 agents, including ticagrelor, in STEMI patients. Usually, NSTEMI course is less dramatic, but
7 whether significant impairment of ticagrelor absorption occurs in these patients, remains
8 unknown.
9

10
11
12
13
14
15
16 Even though ticagrelor shows potent and prompt platelet inhibition, it still fails to
17 provide a desired antiplatelet effect in all STEMI patients during the first hours after the LD.
18
19 At 2 hours after ticagrelor LD up to 60% of STEMI patients may still suffer from inadequate
20 platelet inhibition.[18, 20, 25] Data on the proportion of NSTEMI patients loaded with
21 ticagrelor who are at risk of HPR during peri-PCI period is sparse.
22
23
24
25
26

27
28 The Platelet Inhibition and Patient Outcomes (PLATO) study has shown a remarkable
29 reduction in cardiovascular events and all-cause mortality among ACS patients treated with
30 ticagrelor compared with those receiving clopidogrel. This superiority was demonstrated in
31 most of the analysed subgroups, including patients with STEMI and NSTEMI.[26]
32
33 Nevertheless, epidemiology, clinical approach and early outcomes differ between patients
34 with these two types of AMI, while recommended dosing regimens of ticagrelor are identical
35 in both clinical settings.[2, 3, 27-30]
36
37
38
39
40
41
42

43
44 Currently, there are no data on direct comparison of ticagrelor's pharmacokinetics in
45 the mentioned types of AMI, while STEMI patients may be at risk of having lower ticagrelor
46 plasma concentrations in the most crucial time during the early hours of AMI treatment.[18,
47 22] Similarly, potential differences in ticagrelor's antiplatelet action between STEMI and
48 NSTEMI have not been defined yet. Therefore, we decided to verify whether
49 pharmacokinetics and pharmacodynamics of ticagrelor differ between STEMI and NSTEMI
50 patients. The Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI
51
52
53
54
55
56
57
58
59
60

1
2
3 and NSTEMI Patients (PINPOINT) study is expected to provide a valuable insight into our
4
5 knowledge regarding modern treatment of AMI patients.
6
7

8 **METHODS AND ANALYSIS**

9 **Study objectives**

10
11
12 The PINPOINT study is designed to compare pharmacokinetics and
13
14 pharmacodynamics of ticagrelor and its active metabolite (AR-C124910XX) in patients with
15
16 STEMI and NSTEMI designated to invasive strategy.
17
18
19

20 **Study design**

21
22 The PINPOINT study is a phase IV, single centre, investigator-initiated, prospective,
23
24 observational, pharmacokinetic-pharmacodynamic study. After admission to the study centre
25
26 (Cardiology Clinic, Dr. A. Jurasz University Hospital, Bydgoszcz, Poland) and confirmation
27
28 of STEMI or NSTEMI diagnosis according to the Third Universal Definition of Myocardial
29
30 Infarction,[1] patients will be screened for eligibility for the study. Before any study specific
31
32 procedure, each patient will provide a written informed consent to participate in the trial. All
33
34 included patients will immediately receive orally a 300 mg LD of plain aspirin in integral
35
36 tablets and a 180 mg LD of ticagrelor in integral tablets with 250 mL of tap water.
37
38 Subsequently, all patients will promptly undergo a coronary angiography followed by PCI, if
39
40 required. Blood samples for pharmacokinetic and pharmacodynamic assessment will be
41
42 drawn at eight predefined time points according to the blood sampling schedule already used
43
44 at our site in a previous study (pre-treatment baseline, 30min, 1h, 2h, 3h, 4h, 6h and 12h post
45
46 ticagrelor LD - as shown in Figure 1).[31]
47
48
49
50
51

52 All enrolled patients with the initial AMI diagnosis not confirmed will be excluded
53
54 from the primary analysis. Patients qualified for urgent CABG within the blood sampling
55
56
57
58
59
60

period also will not be included in the analysis. All study participants not receiving PCI will be reported.

Study population

The study population will include consecutive adult, male or non-pregnant female, P2Y12 receptor inhibitor-naive STEMI and NSTEMI patients, designated to invasive strategy. Full list of inclusion and exclusion criteria are presented in Table 1.

Table 1. Inclusion and exclusion criteria of the PINPOINT study.

Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none"> • provision of informed consent prior to any study specific procedure • diagnosis of STEMI or NSTEMI • male or non-pregnant female, 18 years old and older • provision of informed consent for angiography and PCI 	<ul style="list-style-type: none"> • treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrolment • hypersensitivity to ticagrelor • current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin • active bleeding • history of intracranial haemorrhage • fibrinolytic treatment during the index event • recent gastrointestinal bleeding (within 30 days) • history of coagulation disorders • history of moderate or severe hepatic impairment • history of major surgery or severe trauma (within 3 months) • second or third degree atrioventricular block during screening for eligibility • patient required dialysis • manifest infection or inflammatory state • Killip class III or IV during screening for eligibility • respiratory failure

- current therapy with strong CYP3A inhibitors or strong CYP3A inducers

NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention;
STEMI: ST-elevation myocardial infarction.

Blood sample processing

Blood samples for pharmacokinetic and pharmacodynamic evaluation will be obtained using a venous catheter (18G) inserted into a forearm vein at eight prespecified time-points (before ticagrelor LD, 30min, 1h, 2h, 3h, 4h, 6h and 12h post ticagrelor LD - Figure 1).

Venous blood for the pharmacokinetic evaluation will be collected into lithium-heparin vacuum test-tubes. Immediately after collection, each sample will be placed on dry ice and will be transferred to the central laboratory. Subsequently, within 20 minutes from collection, the blood will be centrifuged at 1500 g for 12 minutes at 4°C. Within 10 minutes post-centrifugation, obtained plasma samples will be stored at temperature below -60°C until analyzed.

Venous blood for the assessment of pharmacodynamics with VASP assay and multiple electrode aggregometry (MEA) will be collected into trisodium citrate and hirudin vacuum test-tubes, respectively. The first 3-5 mL of blood will be discarded to avoid spontaneous platelet activation. Pharmacodynamic analysis will be performed for each sample within 24h and 60min from blood collection for VASP and MEA, respectively.

Assessment of pharmacokinetics

Blood plasma concentrations of ticagrelor and AR-C124910XX in samples obtained at all eight predefined time points (Figure 1) will be evaluated using liquid chromatography mass spectrometry coupled with tandem mass spectrometry, as previously described.[18, 32] Briefly, ticagrelor and AR-C124910XX will be extracted using 4°C methanol solution containing [2H7]ticagrelor internal standard (TM-ALS-13-226-P1, ALSACHIM, France),

1
2
3 while calibration curves will be obtained using ticagrelor (SVI-ALS-13-146, ALSACHIM,
4 France) and AR-C124910XX (TM-ALS-13-193-P1, ALSACHIM, France) standards.
5
6 Analysis will be performed using the Shimadzu UPLC Nexera X2 system consisting of LC-
7
8 30AD pumps, SIL-30AC Autosampler, CTO-20AC column oven, FCV-20-AH2 valve unit,
9
10 and DGU-20A5R degasser coupled with Shimadzu 8030 ESI-QqQ mass spectrometer. Lower
11
12 limits of quantification are 4.69 ng/mL for both ticagrelor and AR-C124910XX.
13
14

15 16 17 **Assessment of pharmacodynamics**

18
19 Platelet VASP assay (Biocytex, Inc., Marseille, France) will be applied to all study
20
21 participants at all predefined time points. MEA (Roche Diagnostics International Ltd.,
22
23 Rotkreuz, Switzerland) will be used at all predefined time points (Figure 1) for all study
24
25 participants with the exception of those treated with glycoprotein IIb/IIIa (GP IIb/IIIa)
26
27 receptor inhibitors as this therapy may affect the results of platelet reactivity assessment with
28
29 MEA (Figure 2). Pharmacodynamic assessment with VASP and MEA will be performed
30
31 according to the manufacturers' instructions, as previously described.[33, 34] HPR will be
32
33 defined as platelet reactivity index (PRI) >50% and area under the aggregation curve >46
34
35 units, when evaluated with VASP and MEA, respectively.[35]
36
37
38
39

40 41 **Treatment**

42
43 All patients included in the trial will be treated according to the current European
44
45 Society of Cardiology (ESC) guidelines.[2, 3, 36] Standard therapy will include aspirin,
46
47 ticagrelor, beta-blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin
48
49 II receptor blockers, if not contraindicated. Morphine will be used at the discretion of the
50
51 ambulance staff and the attending physician. The type of implanted stent and the choice of the
52
53 access site for the coronary invasive procedure (radial or femoral) will be at the discretion of
54
55 the operator. During the periprocedural period, all study participants will receive
56
57 unfractionated heparin in body weight adjusted dose according to the ESC
58
59
60

1
2
3 recommendations.[2, 3, 36] Administration of GP IIb/IIIa receptor inhibitors will be restricted
4
5 only to bailout situations. Interventional cardiologists will be encouraged to use manual
6
7 thrombectomy in case of visible thrombus.
8
9

10 11 **Study endpoints**

12 The primary end-point of the study is area under the plasma concentration-time curve
13 (AUC₍₀₋₆₎) for ticagrelor for the first 6 hours after LD of ticagrelor. Secondary end-points
14 include AUC₍₀₋₆₎ for AR-C124910XX, area under the plasma concentration-time curve
15 (AUC₍₀₋₁₂₎) for ticagrelor for the first 12 hours after LD of ticagrelor, AUC₍₀₋₁₂₎ for AR-
16 C124910XX, maximum concentration (C_{max}) of ticagrelor and AR-C124910XX, time to
17 maximum concentration (t_{max}) for ticagrelor and AR-C124910XX, PRI assessed by the VASP
18 assay, platelet reactivity assessed by MEA, percentage of patients with HPR after ticagrelor
19 LD assessed with the VASP assay and MEA, time to reach platelet reactivity below the cut-
20 off value for HPR evaluated with the VASP assay and MEA.
21
22
23
24
25
26
27
28
29
30
31
32

33 34 **Statistical analysis**

35 The continuous variables in the both study groups will be compared by t-test for
36 normally distributed values as assessed by Kolmogorov-Smirnov test. Otherwise, the Mann-
37 Whitney U test will be used. Proportions will be compared by the chi-square test when
38 appropriate. A single linear regression analysis will be performed and will be followed by a
39 multiple regression analysis in case any variables are found to significantly affect the study
40 primary end-point. Pharmacokinetic calculations and plots will be made using dedicated
41 software.
42
43
44
45
46
47
48
49
50
51

52 53 **Determination of sample size**

54 Since there is no reference study comparing pharmacokinetics of ticagrelor in STEMI
55 and NSTEMI patients, we decided to perform an internal pilot study of at least 15 patients
56
57
58
59
60

1
2
3 with each type of AMI for estimating the final sample size. Eventually, the pilot study
4
5 population comprised of 45 patients (15 with NSTEMI and 30 with STEMI). This included all
6
7 consecutively enrolled study participants who entered the trial until the minimum planned
8
9 number of patients was reached in the less numerous group (NSTEMI).
10

11 The means and standard deviations of $AUC_{(0-6)}$ for ticagrelor in the first 30 STEMI
12
13 patients and 15 NSTEMI patients were 2382 ± 2282 and 6406 ± 4082 ng*h/ml, respectively.
14
15 Based on these results and assuming a two-sided alpha value of 0.05, we calculated, using the
16
17 t-test for independent variables, that enrolment of at least 23 patients in each study arm would
18
19 provide a 95% power to demonstrate a significant difference in $AUC_{(0-6)}$ for ticagrelor
20
21 between patients with different type of MI.
22
23

24 25 26 **Study limitations**

27
28 Several limitations of our study have to be acknowledged. First, the anticipated trial
29
30 population will not be sufficient to evaluate clinical end-points and most likely to perform
31
32 subgroup analyses. Second, patients receiving morphine are not excluded from the study,
33
34 which may result in the baseline characteristics differences between the examined groups.
35
36 Third, morphine is used at the discretion of the paramedics or the attending physicians,
37
38 although we encourage the medical staff to administer a standardized dose of 5 mg
39
40 intravenously, if required in any potential or actual study participant. On the other hand, even
41
42 though it may be perceived as a limitation, this will enable us to obtain a real life data and will
43
44 not create artificially selected population.
45
46
47

48 49 **ETHICS AND DISSEMINATION**

50 51 **Ethics**

52
53 The study will be conducted in accordance with the principles contained in the
54
55 Declaration of Helsinki and Good Clinical Practice guidelines. The study received a
56
57 favourable ethical opinion and approval from the Local Ethics Committee to conduct the
58
59

study (Komisja Bioetyczna Uniwersytetu Mikołaja Kopernika w Toruniu przy Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy; study approval reference number KB 617/2015). Each patient will provide a written informed consent to participate in the study.

Safety

The following safety endpoints will be recorded during the blood sampling period: all-cause death, recurrent myocardial infarction according to the Third Universal Definition of Myocardial Infarction, stroke, and transient ischaemic attack according to definitions used in the PLATO trial, definite or probable stent thrombosis according to the Academic Research Consortium criteria, minor and major bleedings according to the TIMI (thrombolysis in myocardial infarction) criteria, dyspnea adverse events according to criteria used in the PLATO trial, bradyarrhythmic events according to criteria used in the PLATO trial.

Present status

The approval of the Local Ethic Committee was obtained on September 29, 2015. On November 9, 2015 the PINPOINT study was registered on ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT02602444). The first patient was enrolled in November 2015. The baseline characteristics of patients included in the pilot study are presented in Table 2.

Table 2. Baseline characteristics of patients included in the internal pilot study.

	STEMI (n=30)	NSTEMI (n=15)	p value
Age [years]	62.3 ± 8.8	63.9 ± 9.7	0.51
Age ≥70 years	6 (20.0%)	4 (26.7%)	0.89
Female	6 (20.0%)	5 (33.3%)	0.53
BMI [kg/m ²]	28.6 ± 4.1	27.8 ± 4.2	0.76
Hypertension	10 (33.3%)	10 (66.7%)	0.036
Diabetes mellitus	6 (20.0%)	2 (13.3%)	0.89

Dyslipidaemia	27 (90.0%)	14 (93.3%)	0.85
Current smoker	13 (43.3%)	5 (33.3%)	0.52
Prior MI	0	2 (13.3%)	n/a
Prior PCI	2 (6.7%)	3 (20.0%)	0.4
Prior CABG	0	0	n/a
Congestive heart failure	0	0	n/a
Nonhaemorrhagic stroke	0	0	n/a
Peripheral arterial disease	1 (3.3%)	2 (13.3%)	0.21
Chronic renal disease	0	0	n/a
Chronic obstructive pulmonary disease	0	0	n/a
Gout	1 (3.3%)	1 (6.7%)	n/a
Morphine use during current MI	17 (56.7%)	6 (40.0%)	0.29

BMI: body mass index; CABG: coronary artery bypass surgery; MI: myocardial infarction; n/a: not available; NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction. Data are shown as mean \pm standard deviation or number (%).

Dissemination of results

Results of the PINPOINT study will be disseminated through conference presentations and peer-reviewed journals. The results will also be made available through study record website at ClinicalTrials.gov.

SUMMARY

Is it unknown whether ticagrelor's pharmacokinetic profile and antiplatelet effects are uniform in STEMI and NSTEMI patients, who are a very heterogeneous population. The PINPOINT trial is expected to be the first study to elucidate whether diagnosis of STEMI is associated with poorer absorption and subsequently weaker antiplatelet action of ticagrelor when compared with NSTEMI patients.

Contributors

JK and PA conceived the study. JK and PA wrote the study protocol with consultation from MO, JS, KO, KB, MKr, GS, MM and MKo. Subsequently JK, PA, MO, JS, KO, KB, MKr, GS, MM and MKo revised the manuscript critically for important intellectual content. All the authors read and approved the final manuscript.

Competing interests

Dr. Jacek Kubica received a consulting fee from AstraZeneca. Dr. Marek Koziński received honoraria for lectures from AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Funding

The study is funded by Collegium Medicum of Nicolaus Copernicus University and did not receive any external funding.

Ethics approval

Local Ethics Committee: Komisja Bioetyczna Uniwersytetu Mikołaja Kopernika w Toruniu przy Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy (study approval reference number: KB 617/2015).

References

1. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Eur Heart J* 2012;33:2551-67.
2. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2012;33:2569-619.

- 1
2
3 3. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute
4 coronary syndromes in patients presenting without persistent ST-segment elevation: Task
5 Force for the Management of Acute Coronary Syndromes in Patients Presenting without
6 Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur*
7 *Heart J* 2016;37:267-315.
8
9
10
11
12
- 13
14 4. Adamski P, Adamska U, Ostrowska M, et al. New directions for pharmacotherapy in the
15 treatment of acute coronary syndrome. *Expert Opin Pharmacother* 2016;17:2291-306.
16
17
- 18
19 5. Kubica J. The optimal antiplatelet treatment in an emergency setting. *Folia Med*
20 *Copernicana* 2014;2:73-6.
21
22
- 23
24 6. Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors:
25 collaborative analysis on the role of platelet reactivity for risk stratification after
26 percutaneous coronary intervention. *Eur Heart J* 2015;36:1762-71.
27
28
- 29
30 7. Winter MP, Koziński M, Kubica J, et al. Personalized antiplatelet therapy with P2Y12
31 receptor inhibitors: benefits and pitfalls. *Postępy Kardiol Interwencyjnej* 2015;11:259-80.
32
33
- 34
35 8. Navarese EP, Buffon A, Kozinski M, et al. A critical overview on ticagrelor in acute
36 coronary syndromes. *QJM* 2013;106:105-15.
37
38
- 39
40 9. Adamski P, Koziński M, Ostrowska M, et al. Overview of pleiotropic effects of platelet
41 P2Y12 receptor inhibitors. *Thromb Haemost* 2014;112:224-42.
42
43
- 44
45 10. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and
46 excretion of ticagrelor in healthy subjects. *Drug Metab Dispos* 2010;38:1514-21.
47
48
- 49
50 11. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics,
51 and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with
52 atherosclerosis: a double-blind comparison to clopidogrel with aspirin. *Eur Heart J*
53 2006;27:1038-47.
54
55
- 56
57 12. Varenhorst C, Eriksson N, Johansson Å, et al. Effect of genetic variations on ticagrelor
58
59
60

- 1
2
3 plasma levels and clinical outcomes. *Eur Heart J* 2015;36:1901-12.
- 4
5 13. Teng R, Mitchell P, Butler K. Effect of age and gender on pharmacokinetics and
6
7 pharmacodynamics of a single ticagrelor dose in healthy individuals. *Eur J Clin*
8
9 *Pharmacol* 2012;68:1175-82.
- 10
11 14. Teng R, Mitchell PD, Butler K. Lack of significant food effect on the pharmacokinetics
12
13 of ticagrelor in healthy volunteers. *J Clin Pharm Ther* 2012;37:464-8.
- 14
15 15. Husted SE, Storey RF, Bliden K, et al. Pharmacokinetics and pharmacodynamics of
16
17 ticagrelor in patients with stable coronary artery disease: results from the ONSET-
18
19 OFFSET and RESPOND studies. *Clin Pharmacokinet* 2012;51:397-409.
- 20
21 16. Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine decreases ticagrelor concentrations
22
23 but not its antiplatelet effects: a randomized trial in healthy volunteers. *Eur J Clin Invest*
24
25 2016;46:7-14.
- 26
27 17. Kubica J, Kubica A, Jilma B, et al. Impact of morphine on antiplatelet effects of oral
28
29 P2Y12 receptor inhibitors. *Int J Cardiol* 2016;215:201-8.
- 30
31 18. Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor
32
33 exposure and action in patients with myocardial infarction: the randomized, double-blind,
34
35 placebo-controlled IMPRESSION trial. *Eur Heart J* 2016;37:245-52.
- 36
37 19. Adamski P, Ostrowska M, Sroka WD, et al. Does morphine administration affect
38
39 ticagrelor conversion to its active metabolite in patients with acute myocardial infarction?
40
41 A sub-analysis of the randomized, double-blind, placebo-controlled IMPRESSION trial.
42
43 *Folia Med Copernicana* 2015;3:100-6.
- 44
45 20. Franchi F, Rollini F, Cho JR, et al. Impact of Escalating Loading Dose Regimens of
46
47 Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing
48
49 Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized
50
51 Pharmacokinetic and Pharmacodynamic Investigation. *JACC Cardiovasc Interv*
52
53
54
55
56
57
58
59
60

- 2015;8:1457-67.
21. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y₁₂ receptor antagonist, in healthy subjects. *Eur J Clin Pharmacol* 2010;66:487-96.
 22. Koziński M, Ostrowska M, Adamski P, et al. Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite? The HARMONIC study. *Thromb Haemost* 2016;116:1140-9.
 23. Heestermans AA, van Werkum JW, Taubert D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. *Thromb Res* 2008;122:776-81.
 24. Kubica J, Kozinski M, Navarese EP, et al. Cangrelor: an emerging therapeutic option for patients with coronary artery disease. *Curr Med Res Opin* 2014;30:813-28.
 25. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. *J Am Coll Cardiol* 2013;61:1601-6.
 26. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med* 2009;361:1045-57.
 27. McManus DD, Gore J, Yarzebski J, et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. *Am J Med* 2011;124:40-7.
 28. Gierlotka M, Zdrojewski T, Wojtyniak B, et al. Incidence, treatment, in-hospital mortality and one-year outcomes of acute myocardial infarction in Poland in 2009-2012-nationwide AMI-PL database. *Kardiol Pol* 2015;73:142-58.
 29. Mandelzweig L, Battler A, Boyko V, et al. The Second Euro Heart Survey on Acute Coronary Syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean basin in 2004. *Eur Heart J* 2006;27:2285-93.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
30. Terkelsen CJ, Lassen JF, Norgaard BL, et al. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. *Eur Heart J* 2005;26:18-26.
 31. Kubica J, Adamski P, Ostrowska M, et al. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. *Trials* 2015;16:198.
 32. Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2010;878:2299-306.
 33. Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. *Eur J Pharmacol* 2014;742:47-54.
 34. Koziński M, Obońska K, Stankowska K, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. *Cardiol J* 2014;21:547-56.
 35. Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. *Eur Heart J* 2014;35:209-15.
 36. Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS): Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J* 2014;35:2541-619.

1
2
3 **Figure 1.** The PINPOINT study schema.
4

5
6 ASA: aspirin; LD: loading dose; NSTEMI: non-ST-elevation myocardial infarction; PCI:
7
8 percutaneous coronary intervention; PD: pharmacodynamics; PK: pharmacokinetics; STEMI:
9
10 ST-elevation myocardial infarction.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **Figure 2.** Platelet reactivity evaluation schedule for the PINPOINT study.
4

5
6 GP IIb/IIIa: glycoprotein IIb/IIIa; MEA: multiple electrode aggregometry; VASP:

7
8 vasodilator-stimulated phosphoprotein.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1. PINPOINT study schema.

ASA: aspirin; LD: loading dose; NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; PD: pharmacodynamics; PK: pharmacokinetics; STEMI: ST-elevation myocardial infarction.

254x190mm (300 x 300 DPI)




Figure 2. Platelet reactivity evaluation schedule for the PINPOINT study.
 GP IIb/IIIa: glycoprotein IIb/IIIa; MEA: multiple electrode aggregometry; VASP: vasodilator-stimulated phosphoprotein.

254x190mm (300 x 300 DPI)

View Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

Protocol for the PINPOINT study.

	Item No	Recommendation
✓ Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
✓ Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
✓ Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
✓ Study design	4	Present key elements of study design early in the paper
✓ Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
✓ Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
✓ Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
✓ Data sources/measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
✓ Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
✓ Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Comment [PA1]: Will be published in the main publication with final results of the study.

Comment [PA2]: Will be published in the main publication with final results of the study.

Results		
✓ Participants	13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
✓ Descriptive data	14	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
✓ Outcome data	15	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information		
✓ Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

Comment [PA3]: Will be published in the main publication with final results of the study.

Comment [PA4]: Will be published in the main publication with final results of the study.

Comment [PA5]: Will be published in the main publication with final results of the study.

Comment [PA6]: Will be published in the main publication with final results of the study.

Comment [PA7]: Will be published in the main publication with final results of the study.

Comment [PA8]: Will be published in the main publication with final results of the study.

BMJ Open

Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single centre study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-013218.R3
Article Type:	Protocol
Date Submitted by the Author:	30-Jan-2017
Complete List of Authors:	Adamski, Piotr; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Principles of Clinical Medicine Ostrowska, Małgorzata; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Principles of Clinical Medicine Sikora, Joanna; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Pharmacology and Therapy Obońska, Karolina; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Cardiology and Internal Medicine Buszko, Katarzyna; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Theoretical Foundations of Biomedical Science and Medical Informatics Krintus, Magdalena; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Laboratory Medicine Sypniewska, Grazyna; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Laboratory Medicine Marszał, Michał; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Medicinal Chemistry Kozinski, Marek; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Principles of Clinical Medicine Kubica, Jacek; Uniwersytet Mikolaja Kopernika Collegium Medicum, Department of Cardiology and Internal Medicine
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Pharmacology and therapeutics
Keywords:	NSTEMI, pharmacodynamics, pharmacokinetics, STEMI, ticagrelor

SCHOLARONE™
Manuscripts

Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single centre study

Piotr Adamski,^{1†} Małgorzata Ostrowska,¹ Joanna Sikora,² Karolina Obońska,³ Katarzyna Buszko,⁴ Magdalena Krintus,⁵ Grażyna Sypniewska,⁵ Michał Piotr Marszałł,⁶ Marek Koziński,¹ Jacek Kubica³

¹Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

²Department of Pharmacology and Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

³Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁴Department of Theoretical Foundations of Biomedical Science and Medical Informatics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁵Department of Laboratory Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

⁶Department of Medicinal Chemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

† Corresponding author

Address for correspondence: Piotr Adamski, Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, 9 Skłodowskiej-Curie Street, 85-094 Bydgoszcz, Poland; Tel.: +48 52 5854023, Fax: +48 52 5854024; E-mail: piotr.adamski@wp.eu

Keywords: NSTEMI, pharmacodynamics, pharmacokinetics, STEMI, ticagrelor

Word count: 3105

ABSTRACT

Introduction

The most common classification of acute myocardial infarction (AMI) is based on electrocardiographic findings and distinguishes ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). Both types of AMI differ concerning their epidemiology, clinical approach and early outcomes. Ticagrelor is a P2Y₁₂ receptor inhibitor, constituting the first line treatment for STEMI and NSTEMI. According to available data, STEMI may be associated with lower plasma concentration of ticagrelor in the first hours of AMI, but currently there are no studies directly comparing ticagrelor pharmacokinetics or antiplatelet effect in STEMI versus NSTEMI patients.

Methods and analysis

The PINPOINT study is a phase IV, single centre, investigator-initiated, prospective, observational study designed to compare the pharmacokinetics and pharmacodynamics of ticagrelor in STEMI and NSTEMI patients assigned to the invasive strategy of treatment. Based on an internal pilot study, the trial is expected to include at least 23 patients with each AMI type. All subjects will receive a 180 mg loading dose of ticagrelor. The primary endpoint of the study is the area under the plasma concentration-time curve ($AUC_{(0-6)}$) for ticagrelor during the first 6 hours after the loading dose. Secondary endpoints include various pharmacokinetic features of ticagrelor and its active metabolite (AR-C124910XX), and evaluation of platelet reactivity by the VASP assay and multiple electrode aggregometry. Blood samples for the pharmacokinetic and pharmacodynamic assessment will be obtained at pre-treatment, 30min, 1h, 2h, 3h, 4h, 6h and 12h post ticagrelor loading dose.

Ethics and dissemination

1
2
3 The study received approval from the Local Ethics Committee (Komisja Bioetyczna
4 Uniwersytetu Mikołaja Kopernika w Toruniu przy Collegium Medicum im. Ludwika
5 Rydygiera w Bydgoszczy; approval reference number KB 617/2015). The study results will
6
7
8
9
10 be disseminated through conference presentations and peer-reviewed journals.

11
12
13 **Trial Registration:** ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015)
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STRENGTHS AND LIMITATIONS

- This is the first study to provide prospective head-to-head comparison of ticagrelor pharmacokinetics and pharmacodynamics in STEMI versus NSTEMI patients assigned to the invasive strategy.
- Plasma concentrations of ticagrelor and its active metabolite will be assessed with liquid chromatography mass spectrometry coupled with tandem mass spectrometry.
- The antiplatelet effect of ticagrelor will be evaluated with two commonly recognized methods: the vasodilator-stimulated phosphoprotein (VASP) assay and multiple electrode aggregometry.
- As this is a purely pharmacokinetic/pharmacodynamic study, it is likely that the anticipated trial population will not be sufficient to evaluate clinical endpoints or perform subgroup analyses.
- Patients receiving morphine are not excluded from the study, which may result in differences in the baseline characteristics between the examined groups, but this will enable us to obtain data in a real-world setting and will not create an artificially selected population.

INTRODUCTION

Background

The routine classification of acute myocardial infarction (AMI) applied in everyday practice to facilitate the choice of treatment strategy is based on electrocardiographic findings, and distinguishes ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI).[1]

In STEMI, usually caused by acute total occlusion of a coronary artery, immediate primary percutaneous coronary intervention (PCI) is the mainstay of treatment.[2] In contrast to STEMI, the therapeutic strategy for NSTEMI and its timing depend on the risk stratification.[3] Complementary to coronary revascularization, dual antiplatelet therapy, consisting of aspirin on top of a P2Y₁₂ receptor inhibitor, remains the cornerstone of pharmacological treatment in both forms of AMI.[4, 5] Inadequate platelet inhibition during treatment with P2Y₁₂ receptor inhibitors, defined as high platelet reactivity (HPR), is an important risk factor for stent thrombosis and may be associated with increased mortality.[6, 7] Therefore, effective and rapid suppression of platelet activation is pivotal in AMI patients treated with PCI.

Ticagrelor is a reversible, oral P2Y₁₂ receptor inhibitor, recommended as the first line treatment for STEMI and NSTEMI.[8, 9] It is characterized by linear pharmacokinetics and does not require hepatic metabolism to exert its antiplatelet action. Nevertheless, it is extensively metabolised by hepatic CYP3A enzymes.[10] AR-C124910XX is the major active metabolite of ticagrelor and it produces similar antiplatelet effect as the parent drug. After oral ingestion of ticagrelor, AR-C124910XX quickly appears in the circulation and reaches approximately one third of ticagrelor plasma concentration.[10] The remaining 9 of identified ticagrelor metabolites appear to be clinically insignificant. Ticagrelor- and AR-C124910XX-induced platelet inhibition is proportional to their plasma concentrations.[11]

Rationale

Impact of numerous clinical features on plasma concentration and pharmacodynamics of ticagrelor has been inspected. Genetic effects, gender, age, concomitant food intake or preloading with clopidogrel have at most minimal influence on the pharmacokinetics of ticagrelor and no clinically significant differences in the degree of platelet inhibition have been reported regarding these factors.[12-15] On the other hand, morphine administration has been shown to affect ticagrelor pharmacokinetic profile, as well as its antiplatelet effect, not only in healthy volunteers, but also in AMI patients.[16-18] The negative impact of morphine on the intestinal absorption has been proposed as an explanation for the observed interactions, while no evidence was found in support of the influence of morphine on conversion of ticagrelor into its active metabolite.[18, 19] Importantly, STEMI, as opposed to NSTEMI, has also been postulated to affect ticagrelor pharmacokinetics. Franchi et al. reported that ticagrelor exposure is attenuated and delayed not only in STEMI patients receiving morphine, but also in opioid-naive STEMI subjects.[20] This may indicate that morphine is not exclusively responsible for the lower concentration of ticagrelor observed in STEMI patients when compared with healthy volunteers or stable coronary artery disease patients.[15, 20, 21] Moreover, sub-analyses of two pharmacokinetic/pharmacodynamic trials suggest that STEMI in comparison with NSTEMI is independently associated with lower plasma concentration of ticagrelor.[18, 22]

Although mechanistic studies are lacking, diminished plasma concentration of ticagrelor after the loading dose (LD) observed in STEMI patients is most likely related to impaired bioavailability of ticagrelor in this setting. Adrenergic activation, decreased cardiac output, haemodynamic instability and vasoconstriction of peripheral arteries, more frequently observed in STEMI patients, lead to selective shunting of blood flow in order to maintain sufficient perfusion of vital organs.[23, 24] This chain of events eventually may cause

1
2
3 intestinal hypoperfusion, which together with emesis could potentially explain the poorer
4
5 absorption of oral agents, including ticagrelor, seen in STEMI patients. The course of
6
7 NSTEMI is usually less dramatic, but it remains unknown whether significant impairment of
8
9 ticagrelor absorption occurs in these patients.
10

11
12 Even though ticagrelor shows potent and prompt platelet inhibition, it still fails to
13
14 provide a desired antiplatelet effect during the first hours after the LD in all STEMI patients.
15
16 At 2 hours after ticagrelor LD up to 60% of STEMI patients may still suffer from inadequate
17
18 platelet inhibition.[18, 20, 25] Data on the proportion of NSTEMI patients loaded with
19
20 ticagrelor who remain at risk of HPR during the peri-PCI period is sparse.
21

22
23 The Platelet Inhibition and Patient Outcomes (PLATO) study has shown a remarkable
24
25 reduction in cardiovascular events and all-cause mortality among acute coronary syndrome
26
27 patients treated with ticagrelor compared with those receiving clopidogrel. This superiority
28
29 was demonstrated in most of the analysed subgroups, including patients with STEMI and
30
31 NSTEMI.[26] Nevertheless, epidemiology, clinical approach and early outcomes differ
32
33 between patients with these two types of AMI, while recommended dosing regimens of
34
35 ticagrelor are identical in both clinical settings.[2, 3, 27-30]
36
37

38
39 Currently, there are no data directly comparing ticagrelor pharmacokinetics in the
40
41 mentioned types of AMI, while STEMI patients may be at risk of having lower ticagrelor
42
43 plasma concentration in the most crucial time during the early hours of AMI treatment.[18,
44
45 22] Similarly, potential differences in ticagrelor antiplatelet action between STEMI and
46
47 NSTEMI have not been defined yet. Therefore, we decided to explore whether the
48
49 pharmacokinetics and pharmacodynamics of ticagrelor differ between STEMI and NSTEMI
50
51 patients. The Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI
52
53 and NSTEMI Patients (PINPOINT) study is expected to provide a valuable insight into our
54
55 knowledge regarding the modern treatment of AMI patients.
56
57
58
59
60

METHODS AND ANALYSIS

Study objectives

The PINPOINT study is designed to compare the pharmacokinetics and pharmacodynamics of ticagrelor and its active metabolite (AR-C124910XX) in patients with STEMI and NSTEMI assigned to the invasive treatment.

Study design

The PINPOINT study is a phase IV, single centre, investigator-initiated, prospective, observational, pharmacokinetic/pharmacodynamic study. After admission to the study centre (Cardiology Clinic, Dr. A. Jurasz University Hospital, Bydgoszcz, Poland) and confirmation of STEMI or NSTEMI diagnosis according to the Third Universal Definition of Myocardial Infarction,[1] patients will be screened for eligibility for the study. Before any study specific procedure, each patient will provide a written informed consent to participate in the trial. All included patients will immediately receive orally a 300 mg LD of plain aspirin in integral tablets and a 180 mg LD of ticagrelor in integral tablets with 250 mL of tap water. Subsequently, all patients will promptly undergo coronary angiography followed by PCI, if required. Blood samples for pharmacokinetic and pharmacodynamic assessment will be drawn at eight predefined time points according to the blood sampling schedule already used at our site in a previous study (pre-treatment baseline, 30min, 1h, 2h, 3h, 4h, 6h and 12h post ticagrelor LD - as shown in Figure 1).[31]

All enrolled patients with finally unconfirmed initial diagnosis of AMI will be excluded from the primary analysis. Patients qualified for urgent CABG within the blood sampling period also will not be included in the analysis. All study participants not receiving PCI will be reported.

Study population

The study population will include consecutive adult, male or non-pregnant female, P2Y12 receptor inhibitor-naive STEMI and NSTEMI patients, assigned to the invasive strategy. Full list of inclusion and exclusion criteria is presented in Table 1.

Table 1. Inclusion and exclusion criteria of the PINPOINT study.

Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none"> • provision of informed consent prior to any study specific procedure • diagnosis of STEMI or NSTEMI • male or non-pregnant female, 18 years old and older • provision of informed consent for angiography and PCI 	<ul style="list-style-type: none"> • treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrolment • hypersensitivity to ticagrelor • current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin • active bleeding <ul style="list-style-type: none"> • history of intracranial haemorrhage • fibrinolytic treatment during the index event • recent gastrointestinal bleeding (within 30 days) • history of coagulation disorders • history of moderate or severe hepatic impairment • history of major surgery or severe trauma (within 3 months) • second or third degree atrioventricular block during screening for eligibility • patient requiring dialysis • manifest infection or inflammatory state • Killip class III or IV during screening for eligibility • respiratory failure • current therapy with strong CYP3A inhibitors or strong CYP3A inducers

NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention;

STEMI: ST-elevation myocardial infarction.

Blood sample processing

Blood samples for the pharmacokinetic and pharmacodynamic evaluation will be obtained using a venous catheter (18G) inserted into a forearm vein at eight prespecified time-points (before ticagrelor LD, 30min, 1h, 2h, 3h, 4h, 6h and 12h post ticagrelor LD - Figure 1).

Venous blood for the pharmacokinetic evaluation will be collected into lithium-heparin vacuum test-tubes. Immediately after collection each sample will be placed on dry ice and transferred to the central laboratory. Subsequently, within 20 minutes from collection, blood specimens will be centrifuged at 1500 g for 12 minutes at 4°C. Within 10 minutes post-centrifugation, obtained plasma samples will be stored at temperature below -60°C until analyzed.

Venous blood for the assessment of pharmacodynamics with the VASP assay and multiple electrode aggregometry (MEA) will be collected into trisodium citrate and hirudin vacuum test-tubes, respectively. The first 3-5 mL of blood will be discarded to avoid spontaneous platelet activation. The pharmacodynamic analysis will be performed for each sample within 24h and 60min from blood collection for VASP and MEA, respectively.

Assessment of pharmacokinetics

Plasma concentration of ticagrelor and AR-C124910XX in samples obtained at all eight predefined time points (Figure 1) will be evaluated using liquid chromatography mass spectrometry coupled with tandem mass spectrometry, as previously described.[18, 32]

Briefly, ticagrelor and AR-C124910XX will be extracted using 4°C methanol solution containing [2H7]ticagrelor internal standard (TM-ALS-13-226-P1, ALSACHIM, France), while calibration curves will be obtained using ticagrelor (SVI-ALS-13-146, ALSACHIM, France) and AR-C124910XX (TM-ALS-13-193-P1, ALSACHIM, France) standards.

Analysis will be performed using the Shimadzu UPLC Nexera X2 system consisting of LC-30AD pumps, SIL-30AC Autosampler, CTO-20AC column oven, FCV-20-AH2 valve unit,

and DGU-20A5R degasser coupled with Shimadzu 8030 ESI-QqQ mass spectrometer. Lower limits of quantification are 4.69 ng/mL for both ticagrelor and AR-C124910XX.

Assessment of pharmacodynamics

Platelet VASP assay (Biocytex, Inc., Marseille, France) will be applied to all study participants at all predefined time points. MEA (Roche Diagnostics International Ltd., Rotkreuz, Switzerland) will be used at all predefined time points (Figure 1) for all study participants with the exception of those treated with glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitors as this therapy may affect the results of platelet reactivity assessment performed with MEA (Figure 2). Pharmacodynamic assessment with VASP and MEA will be performed according to the manufacturers' instructions, as previously described.[33, 34] HPR will be defined as platelet reactivity index (PRI) >50% and area under the aggregation curve >46 units, when evaluated with VASP and MEA, respectively.[35]

Treatment

All patients included in the trial will be treated according to the current European Society of Cardiology (ESC) guidelines.[2, 3, 36] Standard therapy will include aspirin, ticagrelor, beta-blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, if not contraindicated. Morphine will be used at the discretion of the ambulance staff and the attending physician. The type of implanted stent and choice of the access site for coronary invasive procedure (radial or femoral) will be at the discretion of the operator. During the periprocedural period, all study participants will receive unfractionated heparin in body weight adjusted dose according to the ESC recommendations.[2, 3, 36] Administration of GP IIb/IIIa receptor inhibitors will be restricted only to bailout situations. Interventional cardiologists will be encouraged to use manual thrombectomy in case of visible thrombus.

Study endpoints

The primary endpoint of the study is area under the plasma concentration-time curve ($AUC_{(0-6)}$) for ticagrelor during the first 6 hours after the LD of ticagrelor. Secondary endpoints include $AUC_{(0-6)}$ for AR-C124910XX, area under the plasma concentration-time curve ($AUC_{(0-12)}$) for ticagrelor during the first 12 hours after the LD of ticagrelor, $AUC_{(0-12)}$ for AR-C124910XX, maximum concentration (C_{max}) of ticagrelor and AR-C124910XX, time to maximum concentration (t_{max}) for ticagrelor and AR-C124910XX, PRI assessed by the VASP assay, platelet reactivity assessed by MEA, percentage of patients with HPR after ticagrelor LD assessed with the VASP assay and MEA, time to reach platelet reactivity below the cut-off value for HPR evaluated with the VASP assay and MEA.

Statistical analysis

The continuous variables in both study groups will be compared using the t-test for normally distributed values as assessed by Kolmogorov-Smirnov test. Otherwise, the Mann-Whitney U test will be used. Proportions will be compared using the chi-square test when appropriate. A single linear regression analysis will be performed and will be followed by a multiple regression analysis if any variables are found to significantly affect the study primary endpoint. Pharmacokinetic calculations and plots will be made using dedicated software.

Determination of sample size

Since there is no reference study comparing the pharmacokinetics of ticagrelor in STEMI and NSTEMI patients, we decided to perform an internal pilot study of at least 15 patients with each type of AMI for estimating the final sample size. Eventually, the pilot study population comprised of 45 patients (15 with NSTEMI and 30 with STEMI). It included all participants consecutively entering the trial until the number of patients in the smaller group (NSTEMI) reached the prespecified minimal threshold.

The means and standard deviations of $AUC_{(0-6)}$ for ticagrelor in the first 30 STEMI

1
2
3 patients and 15 NSTEMI patients were 2382 ± 2282 and 6406 ± 4082 ng*h/ml, respectively.
4
5 Based on these results and assuming a two-sided alpha value of 0.05, we calculated, using the
6
7 t-test for independent variables, that enrolment of at least 23 patients in each study arm would
8
9 provide a 95% power to demonstrate a significant difference in $AUC_{(0-6)}$ for ticagrelor
10
11 between patients with different types of MI.
12

13 14 15 **Study limitations**

16
17 Several limitations of our study have to be acknowledged. First, it is likely that the
18
19 anticipated trial population will not be sufficient to evaluate clinical endpoints or perform
20
21 subgroup analyses. Second, patients receiving morphine are not excluded from the study,
22
23 which may result in differences in the baseline characteristics between the examined groups.
24
25 Third, morphine is used at the discretion of the paramedics or the attending physicians,
26
27 although we encourage the medical staff to administer a standardized dose of 5 mg
28
29 intravenously, if required in any potential or actual study participant. On the other hand, even
30
31 though it may be perceived as a limitation, this will enable us to obtain data in a real-world
32
33 setting and will not create an artificially selected population.
34
35
36

37 38 **ETHICS AND DISSEMINATION**

39 40 **Ethics**

41
42 The study will be conducted in accordance with the principles contained in the
43
44 Declaration of Helsinki and Good Clinical Practice guidelines. The study received a
45
46 favourable ethical opinion and approval from the Local Ethics Committee (Komisja
47
48 Bioetyczna Uniwersytetu Mikołaja Kopernika w Toruniu przy Collegium Medicum im.
49
50 Ludwika Rydygiera w Bydgoszczy; study approval reference number KB 617/2015). Each
51
52 patient will provide a written informed consent for participation in the study.
53
54
55

56 57 **Safety**

The following safety endpoints will be recorded during the blood sampling period: all-cause death, recurrent myocardial infarction according to the Third Universal Definition of Myocardial Infarction, stroke, and transient ischaemic attack according to definitions used in the PLATO trial, definite or probable stent thrombosis according to the Academic Research Consortium criteria, minor and major bleedings according to the Thrombolysis In Myocardial Infarction (TIMI) criteria, dyspnea adverse events according to criteria used in the PLATO trial, bradyarrhythmic events according to criteria used in the PLATO trial.

Present status

The approval of the Local Ethics Committee was obtained on September 29, 2015. On November 9, 2015 the PINPOINT study was registered on ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT02602444). The first patient was enrolled in November 2015. The baseline characteristics of patients included in the pilot study are presented in Table 2.

Table 2. Baseline characteristics of patients included in the internal pilot study.

	STEMI (n=30)	NSTEMI (n=15)	p value
Age [years]	62.3 ± 8.8	63.9 ± 9.7	0.51
Age ≥70 years	6 (20.0%)	4 (26.7%)	0.89
Female	6 (20.0%)	5 (33.3%)	0.53
BMI [kg/m ²]	28.6 ± 4.1	27.8 ± 4.2	0.76
Hypertension	10 (33.3%)	10 (66.7%)	0.036
Diabetes mellitus	6 (20.0%)	2 (13.3%)	0.89
Dyslipidaemia	27 (90.0%)	14 (93.3%)	0.85
Current smoker	13 (43.3%)	5 (33.3%)	0.52
Prior MI	0	2 (13.3%)	n/a
Prior PCI	2 (6.7%)	3 (20.0%)	0.4
Prior CABG	0	0	n/a
Congestive heart failure	0	0	n/a

Nonhaemorrhagic stroke	0	0	n/a
Peripheral arterial disease	1 (3.3%)	2 (13.3%)	0.21
Chronic renal disease	0	0	n/a
Chronic obstructive pulmonary disease	0	0	n/a
Gout	1 (3.3%)	1 (6.7%)	n/a
Morphine use during current MI	17 (56.7%)	6 (40.0%)	0.29

BMI: body mass index; CABG: coronary artery bypass surgery; MI: myocardial infarction; n/a: not available; NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction. Data are presented as mean \pm standard deviation or number (%).

Dissemination of results

Results of the PINPOINT study will be disseminated through conference presentations and peer-reviewed journals. The results will also be available through the study record website at ClinicalTrials.gov.

SUMMARY

It is unknown whether ticagrelor pharmacokinetic profile and its antiplatelet effect are uniform in STEMI and NSTEMI patients, who are regarded in number of aspects as two distinct populations. The PINPOINT trial is expected to be the first study to elucidate whether STEMI is associated with poorer absorption and subsequently weaker antiplatelet action of ticagrelor in comparison with NSTEMI.

Contributors

JK and PA conceived the study. JK and PA wrote the study protocol with consultation from MO, JS, KO, KB, MKr, GS, MM and MKo. Subsequently JK, PA, MO, JS, KO, KB, MKr, GS, MM and MKo revised the manuscript critically for important intellectual content.

1
2
3 All the authors read and approved the final manuscript.
4
5
6

7 **Competing interests**

8
9 Dr. Jacek Kubica received a consulting fee from AstraZeneca. Dr. Marek Koziński
10 received honoraria for lectures from AstraZeneca. All other authors have reported no
11 relationships relevant to the contents of this paper.
12
13
14

15 **Funding**

16
17 The study is funded by Collegium Medicum of Nicolaus Copernicus University and
18 did not receive any external funding.
19
20
21
22
23

24 **Ethics approval**

25
26 Local Ethics Committee: Komisja Bioetyczna Uniwersytetu Mikołaja Kopernika w
27 Toruniu przy Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy (study approval
28 reference number: KB 617/2015).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Eur Heart J* 2012;33:2551-67.
2. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2012;33:2569-619.
3. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2016;37:267-315.
4. Adamski P, Adamska U, Ostrowska M, et al. New directions for pharmacotherapy in the treatment of acute coronary syndrome. *Expert Opin Pharmacother* 2016;17:2291-306.
5. Kubica J. The optimal antiplatelet treatment in an emergency setting. *Folia Med Copernicana* 2014;2:73-6.
6. Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. *Eur Heart J* 2015;36:1762-71.
7. Winter MP, Koziński M, Kubica J, et al. Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. *Postepy Kardiol Interwencyjnej* 2015;11:259-80.
8. Navarese EP, Buffon A, Kozinski M, et al. A critical overview on ticagrelor in acute coronary syndromes. *QJM* 2013;106:105-15.
9. Adamski P, Koziński M, Ostrowska M, et al. Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. *Thromb Haemost* 2014;112:224-42.
10. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and

- 1
2
3 excretion of ticagrelor in healthy subjects. *Drug Metab Dispos* 2010;38:1514-21.
- 4
5 11. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics,
6
7 and safety of the oral reversible P2Y₁₂ antagonist AZD6140 with aspirin in patients with
8
9 atherosclerosis: a double-blind comparison to clopidogrel with aspirin. *Eur Heart J*
10
11 2006;27:1038-47.
- 12
13 12. Varenhorst C, Eriksson N, Johansson Å, et al. Effect of genetic variations on ticagrelor
14
15 plasma levels and clinical outcomes. *Eur Heart J* 2015;36:1901-12.
- 16
17 13. Teng R, Mitchell P, Butler K. Effect of age and gender on pharmacokinetics and
18
19 pharmacodynamics of a single ticagrelor dose in healthy individuals. *Eur J Clin*
20
21 *Pharmacol* 2012;68:1175-82.
- 22
23 14. Teng R, Mitchell PD, Butler K. Lack of significant food effect on the pharmacokinetics
24
25 of ticagrelor in healthy volunteers. *J Clin Pharm Ther* 2012;37:464-8.
- 26
27 15. Husted SE, Storey RF, Bliden K, et al. Pharmacokinetics and pharmacodynamics of
28
29 ticagrelor in patients with stable coronary artery disease: results from the ONSET-
30
31 OFFSET and RESPOND studies. *Clin Pharmacokinet* 2012;51:397-409.
- 32
33 16. Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine decreases ticagrelor concentrations
34
35 but not its antiplatelet effects: a randomized trial in healthy volunteers. *Eur J Clin Invest*
36
37 2016;46:7-14.
- 38
39 17. Kubica J, Kubica A, Jilma B, et al. Impact of morphine on antiplatelet effects of oral
40
41 P2Y₁₂ receptor inhibitors. *Int J Cardiol* 2016;215:201-8.
- 42
43 18. Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor
44
45 exposure and action in patients with myocardial infarction: the randomized, double-blind,
46
47 placebo-controlled IMPRESSION trial. *Eur Heart J* 2016;37:245-52.
- 48
49 19. Adamski P, Ostrowska M, Sroka WD, et al. Does morphine administration affect
50
51 ticagrelor conversion to its active metabolite in patients with acute myocardial infarction?
52
53
54
55
56
57
58
59
60

- 1
2
3 A sub-analysis of the randomized, double-blind, placebo-controlled IMPRESSION trial.
4
5 *Folia Med Copernicana* 2015;3:100-6.
6
7 20. Franchi F, Rollini F, Cho JR, et al. Impact of Escalating Loading Dose Regimens of
8
9 Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing
10
11 Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized
12
13 Pharmacokinetic and Pharmacodynamic Investigation. *JACC Cardiovasc Interv*
14
15 2015;8:1457-67.
16
17 21. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single
18
19 ascending doses of ticagrelor, a reversibly binding oral P2Y₁₂ receptor antagonist, in
20
21 healthy subjects. *Eur J Clin Pharmacol* 2010;66:487-96.
22
23 22. Koziański M, Ostrowska M, Adamski P, et al. Which platelet function test best reflects the
24
25 in vivo plasma concentrations of ticagrelor and its active metabolite? The HARMONIC
26
27 study. *Thromb Haemost* 2016;116:1140-9.
28
29 23. Heestermans AA, van Werkum JW, Taubert D, et al. Impaired bioavailability of
30
31 clopidogrel in patients with a ST-segment elevation myocardial infarction. *Thromb Res*
32
33 2008;122:776-81.
34
35 24. Kubica J, Kozinski M, Navarese EP, et al. Cangrelor: an emerging therapeutic option for
36
37 patients with coronary artery disease. *Curr Med Res Opin* 2014;30:813-28.
38
39 25. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading
40
41 doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of
42
43 Platelet Inhibitor Drugs) primary PCI study. *J Am Coll Cardiol* 2013;61:1601-6.
44
45 26. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with
46
47 acute coronary syndromes. *N Engl J Med* 2009;361:1045-57.
48
49 27. McManus DD, Gore J, Yarzebski J, et al. Recent trends in the incidence, treatment, and
50
51 outcomes of patients with STEMI and NSTEMI. *Am J Med* 2011;124:40-7.
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28. Gierlotka M, Zdrojewski T, Wojtyniak B, et al. Incidence, treatment, in-hospital mortality and one-year outcomes of acute myocardial infarction in Poland in 2009-2012-nationwide AMI-PL database. *Kardiol Pol* 2015;73:142-58.
 29. Mandelzweig L, Battler A, Boyko V, et al. The Second Euro Heart Survey on Acute Coronary Syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean basin in 2004. *Eur Heart J* 2006;27:2285-93.
 30. Terkelsen CJ, Lassen JF, Norgaard BL, et al. Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort. *Eur Heart J* 2005;26:18-26.
 31. Kubica J, Adamski P, Ostrowska M, et al. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. *Trials* 2015;16:198.
 32. Sillén H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2010;878:2299-306.
 33. Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. *Eur J Pharmacol* 2014;742:47-54.
 34. Koziński M, Obońska K, Stankowska K, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. *Cardiol J* 2014;21:547-56.
 35. Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. *Eur Heart J* 2014;35:209-15.
 36. Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines

1
2
3 on myocardial revascularization: The Task Force on Myocardial Revascularization of the
4 European Society of Cardiology (ESC) and the European Association for Cardio-
5 Thoracic Surgery (EACTS): Developed with the special contribution of the European
6 Association of Percutaneous Cardiovascular Interventions (EAPCI). *Eur Heart J*
7
8
9
10
11
12 2014;35:2541-619.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **Figure 1.** The PINPOINT study schema.
4

5
6 ASA: aspirin; LD: loading dose; NSTEMI: non-ST-elevation myocardial infarction; PCI:
7
8 percutaneous coronary intervention; PD: pharmacodynamics; PK: pharmacokinetics; STEMI:
9
10 ST-elevation myocardial infarction.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2. Platelet reactivity evaluation schedule for the PINPOINT study.

GP IIb/IIIa: glycoprotein IIb/IIIa; MEA: multiple electrode aggregometry; VASP:
vasodilator-stimulated phosphoprotein.

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-013218 on 26 April 2017. Downloaded from <http://bmjopen.bmj.com/> on April 20, 2024 by guest. Protected by copyright.




Figure 1. PINPOINT study schema.

ASA: aspirin; LD: loading dose; NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; PD: pharmacodynamics; PK: pharmacokinetics; STEMI: ST-elevation myocardial infarction.

254x190mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Platelet reactivity evaluation schedule for the PINPOINT study. GP IIb/IIIa: glycoprotein IIb/IIIa; MEA: multiple electrode aggregometry; VASP: vasodilator-stimulated phosphoprotein.

254x190mm (300 x 300 DPI)

Preview Only

STROBE Statement—checklist of items that should be included in reports of observational studies

Protocol for the PINPOINT study.

	Item No	Recommendation
✓ Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
✓ Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
✓ Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
✓ Study design	4	Present key elements of study design early in the paper
✓ Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
✓ Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
✓ Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
✓ Data sources/measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
✓ Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
✓ Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Comment [PA1]: Will be published in the main publication with final results of the study.

Comment [PA2]: Will be published in the main publication with final results of the study.

Results

✓	Participants	13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
✓	Descriptive data	14	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
✓	Outcome data	15	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion			
	Key results	18	Summarise key results with reference to study objectives
	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
	Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information			
✓	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

Comment [PA3]: Will be published in the main publication with final results of the study.

Comment [PA4]: Will be published in the main publication with final results of the study.

Comment [PA5]: Will be published in the main publication with final results of the study.

Comment [PA6]: Will be published in the main publication with final results of the study.

Comment [PA7]: Will be published in the main publication with final results of the study.

Comment [PA8]: Will be published in the main publication with final results of the study.